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2. Abbreviations and definitions 
 
BAC Blood alcohol concentration  
(unit is % m/m or % m/v; g alcohol per 100 gram or 100 ml blood) 
BMP Buprenorphine-maintained patients 
Cmax Maximum concentration level (in blood) 
CNS Central nervous system 
CTT Critical tracking test 
CYP Cytochrome P450 (group of enzymes) 
DAT Divided attention task 
DRUID Driving under the Influence of drugs, alcohol and medicines  
(European project) 
DUI Driving under influence 
DUID Driving under influence of drugs and alcohol 
∆SDLP Delta (change) in SDLP (cm) 
Drug driving Driving after intake of non-alcohol drugs 
Drink driving Driving after intake of alcohol 
DSST Digit symbol substitution test 
DT Determination test 
KSS Karolinska sleepiness scale 
LOD Limit of detection 
LOQ Limit of quantification 
MMP Methadone-maintained patients  
OMT Opioid maintenance treatment 
Per se By itself; in itself 
PBT Postural balance test 
PVT Psychomotor vigilance test 
RTC Road traffic crash 
SCTI Simplified clinical test of impairment 
SDLP Standard deviation of lateral position 
Tmax Time to peak drug concentration in blood/plasma 
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UFOV Useful field of view 
UPLC-MS/MS Ultra-high-performance liquid chromatography tandem mass spectrometry 
QT interval Interval between Q wave and T wave of the heart’s electrical cycle (ECG) 
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5. Summary 
Background/aims 
Driving under the influence of drugs and alcohol are major contributors to the high 
frequency of road traffic crashes globally. Methadone and buprenorphine are among the 
twenty drugs most frequently detected in apprehended drivers suspected of drug driving in 
Norway. However, research investigating drug induced traffic impairment after use of 
methadone and buprenorphine has hardly been performed.  
We aimed to provide an overview of the current scientific literature studying the effects of 
these drugs on crash risk and driving-related performance. We further performed a clinical 
study with actual on-road driving to investigate the acute effects of two single, analgesic 
doses of both methadone and buprenorphine on driving performance in opioid-naïve 
subjects, including neurocognitive tests and pharmacokinetic measures.  
Methods 
For Paper I, we performed a systematic literature review of the current scientific literature 
on traffic-related effects of methadone and buprenorphine. Epidemiological studies on 
traffic risk and experimental studies on performance of traffic relevant skills were included.  
For Papers II and III a clinical trial was performed , using a five-way, double-blind, 
randomized, placebo-controlled, double-dummy, cross-over design, to study on-road driving 
and driving relevant neurocognitive tests in healthy subjects after a single dose of 
methadone (5 or 10 mg) and buprenorphine (0.2 or 0.4 mg). Blood and oral fluid were 
collected throughout the test days. Paper II describes the effects of both drugs on driving 
and neurocognitive tests. In Paper III we analyzed the correlations between drug 
concentrations in blood and effects on the neurocognitive tests including driving, and report 
drug concentrations in blood and oral fluid as well as oral fluid/blood concentration ratios.  
Results and conclusions 
The review revealed that recent epidemiological studies found an increased crash risk in 
male patients treated with methadone and an increased odds ratio for being responsible for 
the crash in injured drivers exposed to either methadone or buprenorphine. Studies on 
patients in opioid maintenance treatment found that both drugs to some degree impaired 
xiv 
 
performance relevant to safe driving. Few studies had investigated the acute effects of 
methadone and buprenorphine on driving related skills in healthy volunteers, and none of 
these tested on-road driving.  
Our clinical trial showed some dose-dependent effects of both drugs on driving related skills, 
even though the administered doses are considered to be low. Buprenorphine 0.4 mg 
significantly impaired driving measured with the standard deviation of lateral position 
(SDLP). Mild effects on driving related skills were measured, but large individual variations 
were observed. For both drugs, four out of 22 subjects terminated the driving test due to 
sleepiness. Some significant positive correlations between drug concentration in blood and 
effects on neurocognitive testing were found for buprenorphine, but not for methadone. 
Large individual differences in pharmacokinetics were observed for both drugs, in blood as 
well as in oral fluid. Concentrations of buprenorphine in blood were in general very low and 
concentrations above the limit of qualification were found only in one third of the blood 
samples. 
Our results imply that caution regarding driving is required when initiating opioid treatment 
and adjusting opioid doses, and patients should thus be informed accordingly, to avoid 
impaired driving and being involved in traffic accidents.  
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6. Sammendrag 
Bakgrunn/formål 
Kjøring i påvirket tilstand er medvirkende årsak til et stort antall trafikkulykker globalt. 
Metadon og buprenorfin er blant de tjue psykoaktive stoffene som oftest påvises i prøver fra 
bilførere mistenkt av politiet for ruspåvirket kjøring i Norge. Det er imidlertid gjennomført 
svært få studier når det gjelder trafikkrelevant påvirkning etter bruk av metadon og 
buprenorfin. 
Vi har undersøkt hva som foreligger av vitenskapelige studier hvor effekten av disse stoffene 
på kjørerelaterte ferdigheter og risiko for trafikkulykker er studert. Videre gjennomførte vi 
en klinisk studie hvor de akutte effektene av lave smertestillende doser av metadon eller 
buprenorfin hos opioid-naive personer ble undersøkt ved reelle kjøring på motorvei, 
inkludert nevrokognitive tester og farmakokinetiske målinger. 
Metode 
Artikkel I er en systematisk litteraturgjennomgang av studier som har undersøkt 
trafikkrelaterte effekter av metadon og buprenorfin. Epidemiologiske studier av trafikkrisiko 
og eksperimentelle studier av effekter på trafikkrelevante ferdigheter ble inkludert. 
Artikkel II og III omfatter en femveis, dobbelt blindet, randomisert, placebokontrollert, 
dobbelt dummy, overkrysningsstudie for å studere effektene på kjøring og kjørerelevante 
ferdigheter av enkeltdoser med metadon (5 eller 10 mg) og buprenorfin (0,2 eller 0,4 mg) 
gitt til friske frivillige. Det ble tatt blod- og spyttprøver i løpet av testdagene. Artikkel II 
beskriver virkningene av begge legemidler på bilkjøring og nevrokognitive tester. I artikkel III 
analyserte vi sammenhengen mellom stoffkonsentrasjoner i blod og effekter på de 
nevrokognitive testene inkludert kjøring. Konsentrasjoner av metadon og buprenorfin ble 
målt i både blod og spytt, samt spytt/blod konsentrasjonsratio, ble rapportert. 
Resultater og konklusjon 
Oversiktsartikkelen viste at nyere epidemiologiske studer har avdekket en økt risiko for å 
være involvert i trafikkulykker for mannlige pasienter som behandles med metadon, og en 
økt sannsynlighet for å være skyld i trafikkulykker for skadde sjåfører som hadde brukt 
metadon eller buprenorfin. Studier av pasienter i vedlikeholdsbehandling med opioider viste 
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at både metadon og buprenorfin til en viss grad svekket trafikkrelevante ferdigheter. Det er 
få studier som har undersøkt de akutte effektene av metadon og buprenorfin når det gjelder 
kjørerelaterte ferdigheter hos friske frivillige, og ingen kjørestudier var gjennomført.  
Den kliniske studien viste doseavhengige effekter av begge legemidler på enkelte av de 
nevrokognitive testene selv om dosene som ble gitt anses lave. Buprenorfin 0,4 mg medførte 
signifikant økning av «vingling i vegbanen» (SDLP). Generelt ble det funnet moderate kliniske 
effekter av legemidlene, men store individuelle forskjeller ble observert. Fire av 22 deltakere 
avsluttet imidlertid kjøringen på grunn av søvnighet etter inntak av både metadon og 
buprenorfin. Signifikant korrelasjon mellom konsentrasjon i blod og noen av effektene på de 
nevokognitiv testene ble vist for buprenorfin, men ikke for metadon. Det ble observert store 
individuelle forskjeller i farmakokinetikk for begge legemidlene, både i blod og spytt. 
Konsentrasjonene av buprenorfin i blod var generelt veldig lave og bare en tredjedel av 
blodprøvene hadde konsentrasjoner av buprenorfin over påvisningsgrensen. 
Resultatene viser at det bør utvises forsiktighet med hensyn til kjøring ved oppstart av 
behandling med opioider og ved justering av opioid-doser. Pasienter som behandles med 
disse legemidlene bør informeres om dette, for å unngå påvirket kjøring og ikke bli involvert 
i trafikkulykker.  
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7. Samenvatting 
Achtergrond/doel 
Rijden onder invloed van alcohol of drugs dragen in belangrijke mate bij aan het hoge aantal 
verkeersongevallen wereldwijd. Methadon en buprenorfine behoren tot de twintig 
geneesmiddelen/drugs die het vaakst worden aangetoond bij bestuurders aangehouden op 
verdenking van het rijden onder invloed in Noorwegen. Onderzoek naar 
verkeersgerelateerde effecten na het gebruik van methadon en buprenorfine is echter 
nauwelijks uitgevoerd. 
We wilden meer te weten te komen over de bestaande kennis over de effecten van deze 
geneesmiddelen op rijvaardigheid en verkeersongevallen. We wilden ook een klinisch 
onderzoek uitvoeren met een rijtest om de acute effecten van analgetische doseringen van 
methadon en buprenorfine bij opiaat-naïeve personen te onderzoeken, inclusief 
neurocognitieve tests en farmacokinetische metingen. 
Methode 
In paper I werd een overzicht gegeven van de huidige wetenschappelijke literatuur over 
verkeersgerelateerde effecten van methadon en buprenorfine. Een systematisch 
literatuuronderzoek werd uitgevoerd om epidemiologische studies en experimentele studies 
naar de invloed van deze stoffen op ongevalsrisico en rijvaardigheid te beoordelen. 
Vervolgens werd een 5-wegs, dubbelblind, gerandomiseerd, placebo-gecontroleerd, dubbel 
dummy crossover onderzoek uitgevoerd (paper II en III) om rijvaardigheid en relevante 
neurocognitieve functies te bestuderen in gezonde personen na een enkele dosering 
methadon (5 of 10 mg) of buprenorfine (0,2 of 0,4 mg). In paper II worden de effecten van 
beide geneesmiddelen op rijvaardigheid en de neurocognitieve tests beschreven. In papier III 
analyseerden we de correlaties tussen geneesmiddelconcentraties in bloed en effecten op 
de neurocognitieve tests en rijvaardigheid, en geneesmiddelconcentraties in bloed en 
speeksel evenals speeksel / bloed-concentratieratio werd gerapporteerd.  
Resultaten en conclusies  
De review bracht aan het licht dat recente epidemiologische studies vonden een verhoogd 
risico op verkeersongevallen bij mannelijke patiënten die werden behandeld met methadon 
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en een verhoogd risico op schuld bij verkeersongevallen na gebruik van methadon en 
buprenorfine. Onderzoek bij patiënten die een onderhoudsbehandeling met opioïden 
ontvangen wees uit dat beide geneesmiddelen tot op zekere hoogte de 
verkeersgerelateerde vaardigheden negatief beïnvloedden. Verder zijn er weinig studies 
uitgevoerd naar de acute effecten van methadon en buprenorfine op rijvaardigheid bij 
gezonde vrijwilligers, en geen rijstudies zijn uitgevoerd.  
De klinische studie toonde enkele dosisafhankelijke effecten van beide geneesmiddelen op 
rijvaardigheid. Buprenorfine 0,4 mg verslechterde aanzienlijk de rijvaardigheid zoals 
gemeten met de standaard deviatie van de laterale positie (SDLP), een maat voor 
slingergedrag. De invloed van opiaten op rijvaardigheid was over het algemeen mild, maar 
individuele variantie was hoog. Vier van de 22 proefpersonen beëindigden voortijdig hun   
rijtest vanwege slaperigheid na beide medicijnen. Enkele correlaties tussen 
geneesmiddelconcentratie in bloed en effecten op neurocognitieve testen werden gevonden 
voor buprenorfine, maar niet voor methadon. Grote individuele variaties werden ook 
waargenomen met betrekking tot de farmacokinetiek van beide geneesmiddelen. 
Concentraties van buprenorfine in het bloed waren in het algemeen laag en in slechts een 
derde van de bloedmonsters was de buprenorfine concentraties boven de 
bepaalbaarheidsgrens. 
De resultaten impliceren dat voorzichtigheid met betrekking tot autorijden vereist is bij het 
initiëren van behandeling met opioïden en bij het aanpassen van opioïde doses, en 
patiënten moeten hierover worden geïnformeerd om rijden onder invloed en 
verkeersongevallen te voorkomen. 
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8. Introduction 
 
8.1.  Prologue 
Driving under the influence (DUI) of drugs and alcohol represents a significant risk of road 
traffic crashes (1, 2). The impairing effects of alcohol on driving are well studied and the 
increased risk of road traffic crashes when driving under the influence of alcohol is 
acknowledged and regulated in most countries through legal limits for driving under the 
influence of alcohol. 
Driving under the influence of psychoactive drugs, i.e. both medicinal and illicit, have over 
the last years also been recognized as a major risk factor for road traffic crashes. This is in 
particular well studied for benzodiazepines (anxiolytic and hypnotic drugs) and cannabis, and 
to some extend for stimulants like amphetamine, methamphetamine and MDMA (3). The 
effects of opioids on driving are, however, less studied, both with regards to the risk of road 
traffic crashes and the impairing effects on driving and driving related skills (3, 4).  
Methadone and buprenorphine are opioids used as analgesics for moderate to severe pain, 
and are also widely used as maintenance treatment to persons with heroin addiction. Both 
drugs are easily available on the illicit street drug market and illegal use is regularly reported. 
Methadone and buprenorphine are both among the top twenty drugs detected in blood 
samples from drivers apprehended by the police for DUI in Norway. Both drugs are potent 
central nervous depressants and are likely to induce driving impairment. Despite the 
frequent use of methadone and buprenorphine, both in opioid maintenance treatment 
(OMT) and illicit use, there are hardly any studies to assess driving relevant impairment after 
administration of methadone or buprenorphine, neither on crash risk nor neurocognitive 
performance. 
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8.2.  Thesis outline 
This thesis includes a summary of the current scientific literature investigating crash risk 
related to exposure to methadone and buprenorphine as OMT as well as experimental 
studies on traffic-relevant neurocognitive performance in opioid-naïve subjects after single 
dose administration and in OMT patients. Furthermore, the thesis includes the first on-road 
driving study, performed after administration of two different single doses of methadone 
and buprenorphine in opioid-naïve subjects, including drug concentrations in blood and oral 
fluid. The thesis does not include control groups administered different alcohol doses, since 
such effects are thoroughly investigated in previous studies performed in Professor 
Ramaekers research group. Furthermore, on-road driving or an experimental study 
investigating traffic-relevant impairment after OMT have not been performed.  
The introduction presents an overview of knowledge regarding DUI of drugs and alcohol, 
prevalence of drug use in normal traffic as well as in fatally injured drivers. The legislation 
regulating DUI in Norway is described, as well as methods for research on crash risk related 
to drug exposure and drug induced traffic impairment. To be able to relate the effects from 
the experimental studies to drug concentrations, relevant information regarding 
pharmacokinetics and pharmacodynamics of opioids in general are included, and for 
methadone and buprenorphine in particular. 
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8.3.  Driving under the influence (DUI) of alcohol or other drugs 
8.3.1. Alcohol 
It is well documented that DUI of alcohol represents one of the most important single 
factors that contributes to motor vehicle crashes worldwide (5-8). A correlation between 
blood alcohol concentrations (BACs) and crash risk has been established (9, 10), as well as a 
strong relationship between BACs and degree of impairment (8).  
Many studies have provided scientific evidence to the effects of alcohol on driving 
performance and traffic safety, e.g. (8-10). Of particular importance for evaluating the 
relationship between BACs and traffic risk were two large-scale case-control studies. “The 
Grand Rapids study” was a large study where 5,985 drivers involved in traffic accidents in 
Grand Rapids, Michigan from July 1962 to June 1963 were compared with a control group of 
7,598 drivers (9). BAC was one of several variables analyzed and a relationship between the 
relative crash risk and BACs was established. The accident risk was shown to be significantly 
higher for drivers with BACs of 0.8 % and higher. This study was later replicated;  data from 
2,871 crashes were collected in Long Beach, California, and Fort Lauderdale, Florida, in 
periods between 1997 and 1999 (10), and other large studies have been performed as well 
(11-13). The crashes were compared to a matched control group of drivers selected from the 
same time and location (10). The results from the Long Beach/Fort Lauderdale study were 
mainly in line with the findings from the Grand Rapids study. However, the elevated relative 
crash risk for BACs higher than 0.1 % were more pronounced than initially estimated. 
The effects of alcohol on neurocognitive functions are well documented in numerous 
studies, especially complex tasks such as (simulated) driving and divided attention (8, 14). It 
is also well established that alcohol produces impairment in a concentration-related manner 
(15, 16). Since alcohol is the best documented drug in relation to driving impairment, it is 
suitable as a benchmark substance for other drugs. Alcohol has been shown to exponentially 
increase crash risk with increasing BACs and is therefore used to determine clinical relevance 
of drug-induced impairment. BAC of 0.05 % is frequently used as a limit for clinical relevant, 
as well as in legislation regulating DUI of alcohol in several countries, since the effects at this 
alcohol level deteriorates traffic relevant skills (17, 18). 
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8.3.2. Non-alcohol drugs 
Over the last years, more attention has been given to the increasing number of road traffic 
crashes related to drug-impaired driving (5, 19, 20), which has been recognized as a public 
safety issue worldwide (21). The most commonly detected psychoactive non-alcohol drugs 
found in blood samples from drug impaired drivers are stimulants (e.g. amphetamines), 
cannabis, benzodiazepines and opioids. These substances might be used both as prescribed 
medicinal drugs, but also as illicit drugs. They are known to be able to impair cognitive and 
psychomotor performance relevant to safe driving (4, 22, 23), but despite this, no other 
psychoactive substances have been examined to the same extent as alcohol.  
Figure 1 illustrates the relative risk of being involved in serious or fatal traffic injuries in 
relation to drug and/or alcohol use. Epidemiological studies of non-alcohol drugs have 
shown that amphetamines have the highest risk of road traffic crash (RTC) involvement, 
when looking at single substances (3). Increased RTC risk has also been found for cocaine, 
cannabis, benzodiazepines and opioids. The use of cannabis, medicinal or illicit opioids 
increases the risk of a serious or fatal injury when involved in a crash with 1-3 times, while 
cocaine increases the risk 2-10 times (1). Combined use of multiple drugs and BACs between 
0.05 to 0.08 % increases the risk 5-30 times. The highest risk (20-200 times greater) is seen in 
cases with alcohol in combination with any psychoactive medicinal or illicit drug, or in cases 
with BAC > 0.12 % (1, 13). However, combined drug and alcohol use might be overlooked, 
since drugs are not always analyzed in all alcohol-positive DUI cases (21), and varies between 
different countries. 
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Figure 1 The figure illustrates the relative risk of being involved in serious or fatal traffic 
injuries in relation to drug and/or alcohol use. The use of medicinal or illicit opioids has a low 
relative risk (with an increase of less than 3 times) of a serious or fatal injury. The 
combination of alcohol with any drug or high BACs have an extremely high increase in 
relative risk of up to 200 times. With permission, www.SWOV.nl 
 
There are few studies on crash risk associated with use of opioids (3), and very few such 
studies investigating methadone and buprenorphine (24-26). Opioids are potent 
psychoactive drugs, and drivers using prescribed opioids have significantly increased risk of 
crash involvement and crash culpability (27). Epidemiological studies performed after 1998 
have found an association between opioid use and RTCs while experimental studies reveal 
only moderate effects of opioids on traffic relevant tests (3, 4). Epidemiological studies on 
methadone and buprenorphine in OMT are few and show divergent results (26, 28).  
A review summarizing experimental studies, published between 1998 and 2015, on 
impairing effects seen after administration of single doses of different psychoactive drugs in 
healthy volunteers,  has recently been performed (4). The review included studies with on-
road driving, driving simulators and performance tests relevant to driving. Regarding the 
opioids, the review concluded that the results were ambiguous(4); some studies found 
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significant effects on cognitive and/or psychomotor performance after administration of 
fentanyl (29) and oxycodone (30), while other studies found no significant effects for 
oxycodone (31, 32) and codeine (33). A different review summarized the acute effects of 
several opioids, including methadone and buprenorphine, and concluded that opioids may 
affect neurocognitive performance depending on the type of opioid and dose administered 
(34). When summarizing the results of studies on driving performance after opioid 
administration it was found that opioids are likely to impair functions relevant to driving and 
are more pronounced in opioid-naïve persons than after long-term use (35). It has been 
suggested that the reason for the variable results could be the sensitivity of the different 
tests and/or the sensitivity of the participants to drug-induced effects (4). Overall, the 
studies showed that opioids can have some impairing effects on cognitive and psychomotor 
performance in healthy volunteers, but the effects seemed moderate with no clear dose 
response relation.  
Some short-term studies suggest a dose-response relationship for impairment using traffic-
relevant tests after methadone and buprenorphine administration (36), but very few such 
studies have however measured drug concentrations in blood. No studies have compared 
the effects of methadone and buprenorphine with the effects of ethanol at different 
concentration levels (28). 
8.3.3. Prevalence of drug use in drivers 
8.3.3.1. Prevalence of drug use in the driving population 
The prevalence of drug use in normal traffic can be examined by road-side surveys, and is 
important to know to be able to estimate the accident risk for different drugs. These results 
are thus combined with the results from blood samples from apprehended and crash-
involved drivers.  
A study from 2011 among the general population of European drivers reported an estimated 
prevalence of alcohol use of 3.48 %, illicit drug use of 1.9 %, impairing medicinal drug use of 
1.36 %, alcohol-drug combination of 0.37 % and drug-drug combination of 0.39 % (37). 
Methadone and buprenorphine were among the medicinal and illicit drugs detected. The 
study included almost 50,000 randomly selected drivers from thirteen countries. The data 
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shows that alcohol by far is the most common psychoactive substance detected in European 
drivers, followed by illicit drugs and medicinal drugs.   
The situation is however different in Norway, where a roadside-survey performed in 2016-
2017 among 5,034 drivers showed a prevalence of 1.7 % for illicit drugs, 3.0 % for medicinal 
drugs and 0.2 % for alcohol (38), see Figure 2. Thus, while medicinal drugs, including 
methadone and buprenorphine, are the most commonly detected drugs in traffic, the 
prevalence of alcohol is very low.  
 
 
Figure 2 Pie chart of the distribution of positive findings of psychoactive substances in oral 
fluid samples from random drivers in regular traffic in Norway in 2016-2017 (independent of 
concentration level) (38). One or more drugs were present in close to 5 % of the cases. 
Approximately half of the samples that tested positive contained one medicinal drug while 
26 % contained one illicit drug. 
 
The most prevalent substances detected in blood samples from drivers apprehended by the 
police suspected of impaired driving in Norway in 2018 were cannabis (42 %), 
benzodiazepines (40 %), alcohol (37 %) and amphetamine (33 %) (39). The most frequently 
detected opioids in blood samples from drivers suspected for DUI of drugs in 2018 were 
8 
 
buprenorphine (3 %), morphine (3 %) and methadone (2 %); and these drugs were all among 
the top twenty drugs detected (39).  
Another Norwegian study investigated 112,348 drivers suspected of drug driving from 1990 
to 2015 (40). In total, 63 % tested positive for drugs, of which 18 % had opioids in their 
blood. Methadone was detected in 1.9 % of the drug positive samples and buprenorphine in 
0.9 %. The number of drivers testing positive for opioids was low compared to other drug 
classes (i.e. alcohol, benzodiazepines, cannabis and stimulants). 
In the majority (98 %) of the blood samples where methadone was detected, in samples 
from apprehended drivers in Norway, illicit drugs were detected in combination (41). The 
extensive use of other drugs among this group makes it difficult to assess the methadone 
effects on psychomotor skills. Furthermore, combination of multiple drug use is associated 
with a higher risk of serious or fatal injuries in crashes than use of medicinal or illicit opioids 
alone, see Figure 1. In the same study, 66 % of the drivers reported prescribed use of 
methadone. If the majority of these drivers are OMT patients, this indicates that a large 
proportion is not following the OMT regulations where use of illicit or sedating drugs is 
prohibited. 
8.3.3.2. Prevalence of drug use in fatal road traffic crashes 
The prevalence of drink and drug driving in fatal road traffic crashes varies between different 
countries. A report from the European DRUID project, which included data collected from 9 
countries between 2006 and 2009, showed that one or more substances (mutually 
exclusive), including methadone, were detected in 28 – 53 % of drivers fatally injured in 
different countries (42). More recent numbers from the United States show that 
approximately one-third of all traffic crash fatalities in 2017 involve drunk drivers (43), while 
close to 44 % of fatally injured drivers tested positive for drugs in 2016 (44). Almost 20 % of 
the fatally injured drug-positive drivers were positive for some opioid, and methadone was 
one of the most frequent opioids detected at 8 % (44). 
In Norway the number of fatalities is low compared with other countries, but further 
reduction in the number of road traffic deaths continues to remain a high priority for the 
authorities, in accordance with the zero vision strategy (45). In 2017, a total of 107 persons 
(approximately 2 per 100 000 inhabitants) were killed in road traffic crashes in Norway (46). 
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This is the lowest number of traffic deaths in 70 years. The low number of fatal traffic 
crashes in Norway compared to the rest of the world is probably due to consistent and high 
focus on traffic safety measures through decades, including legislation, law enforcement for 
DUI cases and public information campaigns. 
Data from killed drivers in Norway between 2005 and 2015 showed that medicinal drugs, i.e. 
benzodiazepines and opioids, were present in approximately 11 % of the cases, and both 
methadone and buprenorphine were detected among the opioid cases (47). The prevalence 
of medicinal opioids, including methadone, in fatally injured drivers was 1.7 % in Norway 
between 2006 and 2009 (42).  
It has been estimated that around 21 % of all fatal road traffic crashes in Norway are related 
to impaired driving due to alcohol, medicinal or illicit drugs (48). This number is probably 
underestimated as 30 % of all fatal crashes are not investigated for alcohol or drugs by 
analyzing blood samples from the drivers (49). The distribution of the different drugs and 
combinations detected in killed rivers in Norway is shown in Figure 3. 
  
10 
 
 
Figure 3 Pie chart of the distribution of drugs and alcohol among drivers fatally injured in 
road traffic crashes in Norway in the period 2005 – 2018 (concentration levels comparable to 
BAC of ≥ 0.02 %). One or more drugs were present in more than 34 % of the cases. Alcohol 
and alcohol in combination with other drug(s) were most frequently observed in samples 
that tested positive. Data from Oslo University Hospital’s RTC research database (n=706).  
 
8.3.4. DUI legislation in Europe 
An important measure to regulate driving behavior is through legislations to make sure that 
the public complies with traffic rules and regulations, e.g. speed limits. Most countries have 
implemented concentrations limits in blood for DUI of alcohol (50, 51). Even though the 
relationship between BAC and degree of impairment is generally accepted, the legal limits 
for driving under the influence of alcohol vary between different countries. E.g. several 
Eastern European countries including Russia have a legal limit of 0.00 %, most Western 
European countries have a legal limit of 0.05 % while England and Northern-Ireland have the 
highest BAC limit of 0.08 %. 
Norway was the first country to establish a per se limit for DUI of alcohol in 1936 (52). The 
BAC limit was initially 0.05 %, but in 2001 the limit was reduced to 0.02 % for political 
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reasons. The intention of the law has been to punish impaired driving and furthermore to 
signal that alcohol use and driving should not be combined.  
As a consequence of the increasing awareness of the impairing effects of non-alcohol drugs, 
and the increase in drug driving, several countries have also introduced legal limits for 
psychoactive drugs other than alcohol (36, 53-55). There are three types of principles 
applied for driving under the influence of drugs (DUID) legislation: impairment laws, zero 
tolerance laws and per se limits. Throughout Europe multiple approaches have been 
introduced, e.g. zero-limits and LOQ-limits, per se limits, and impairment laws (56).  
Legislative per se limits were first introduced in Denmark in 2007 (54), in Norway in 2012 
(36), in England and Wales in 2015 (53), and in the Netherlands in 2017 (55). 
Norway was the first country to implement limits for graded sanctions for non-alcohol drugs 
in addition to per se limits in the Road Traffic Act (36). Per se limits have been established for 
28 psychoactive drugs, while limits for graded sanctions, corresponding to the degree of 
impairment corresponding to BACs of 0.05 and 0.12 %, have been established for 22 of the 
28 drugs. The drugs include several benzodiazepines, stimulants like amphetamines and 
MDMA, cannabis, GHB and opioids including methadone and buprenorphine. After the 
implementation of the per se law the number of blood samples collected in suspected DUID 
cases increased by 20 % (57) and a reduction of medicinal and illicit drug use among the 
general driving population in the southeastern parts of Norway has been observed (38).  
8.4.  Research on impairing effects of drugs on driving 
Driving is a complex task requiring integration of psychomotor, cognitive, and visual-spatial 
skills, decision making, divided attention, working memory, and behavioral and emotional 
control (58, 59). Epidemiological studies can be used to study crash risk and crash culpability, 
while driving related skills can be tested using experimental studies. In addition, real-life 
studies, like DUID cases and drivers involved in road traffic crashes, provide information on 
the effects of substance use on safe driving. There are distinct advantages and limitations of 
the different types of studies (see also sections 8.4.1 and 8.4.2); therefore, all types of 
studies are essential to assess the effects of substance use on driving (60). E.g. while 
epidemiological studies have an observational approach and describe how real-life drug-
exposed drivers perform in normal road traffic, experimental studies are essential to 
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investigate the potential a specific psychoactive drug has to induce traffic-relevant 
impairment.  
For alcohol, a strong correlation between crash risk and BACs has been established, as for 
the relationship between BACs and impairment (61). Less documentation exists for other 
psychoactive substances. 
8.4.1. Crash risk investigated by epidemiological studies 
Epidemiological studies are used to determine crash risk in large populations (3, 60). One 
main advantage of epidemiological studies is that actual driving situations are observed. 
Thereby factors other than specific drug effects are also taken into account, such as insight 
in driving ability, willingness to drive after taking the drug, ability to compensate for 
impairing effects, etc. Furthermore, epidemiological studies allow a large number of drivers 
to be included, and hard endpoints relevant to traffic safety, such as road traffic crashes or 
fatalities, are often studied. 
The main limitations of epidemiological studies are selection bias, information bias, and 
confounders (60). Selection bias is caused by the selection of individuals. Randomization of 
selection of drivers must be proper to ensure that the sample is representative for the 
population intended to be studied. E.g. if participation is voluntary, persons using 
psychoactive drugs might refuse to participate, leading to an underestimation of drug use. 
By using data from road traffic registries high participation rates can be attained and this 
ensures that the drivers are representative to the general driving population. Examples of 
information bias are incorrect classification of substance exposure or different classification 
methods for cases than for controls.  Another contributor to information bias is studies 
based on self-reported drug use or crash involvement. Confounders are variables that might 
affect the crash risk estimates, like age, sex, driving experience, time of day, personality, 
impulsivity, or cultural aspects. E.g. the time of day or the day of the week could have 
significant influence on the odds ratio of crash risk as the prevalence of use of certain drugs 
and types of persons driving at different times of the day are different in weekends and at 
night-time compared to everyday and daytime (2, 38). Another limitation regarding 
information from epidemiological studies is that few studies have provided estimates of 
crash risk related to drug dose or drug concentrations in blood (62-64). Few such studies 
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have been performed due to the small number of cases with known drug concentrations in 
blood, resulting in a low statistical power.  
Epidemiological studies can be divided into the following types:  
1) Pharmacoepidemiological Cohort Studies on road traffic crash (RTC) involvement 
2) Case-Crossover Studies 
3) Case-Control Studies on alcohol and drug use in RTC-involved drivers compared to 
non-RTC-involved drivers 
4) Responsibility Studies, i.e. studies on alcohol and drug use among drivers responsible 
for RTCs compared with non-responsible RTC-involved drivers 
 
8.4.1.1. Pharmacoepidemiological cohort studies on RTC involvement  
These studies compare the crash involvement between two groups, typically one group 
exposed to a psychoactive substance and a non-exposed control group. Drug exposure is 
usually based on records in prescription registries, while crash involvement cases are found 
in road traffic crash databases, hospital or police records, or insurance databases.  
The strengths of these studies are that drivers in actual traffic are studied and that a large 
number of drivers (and controls) can be included. Furthermore, it allows calculation of crash 
risk associated with prescription of medicinal drugs. Limitations are that prescription data 
only provide information on whether medicinal drugs are dispensed at a pharmacy, but not 
if they are used or used as prescribed. Furthermore, the disease initiating the prescription of 
a medicinal drug may itself be deleterious to safe driving, and any use of additional 
medicinal or illicit drugs that can influence driving skills is not known. RTC involvement does 
not provide information on responsibility as the driver might not be the one responsible for 
the accident.  
8.4.1.2. Case-crossover studies 
A case-crossover study examines the crash rate in a cohort of drivers who have received a 
prescription drug. With a case-crossover study design the drivers are their own controls; i.e. 
the drivers which have taken a drug are compared with themselves when they have not 
taken the drug. The advantage of cases being their own controls is that many confounders 
can be eliminated, such as age, sex, driving experience and personality. On the other hand, it 
14 
 
might in some cases be difficult to distinguish between the underlying disease itself, which 
may also influence the crash risk, and the prescribed drug.  
8.4.1.3. Case-control studies 
Case-control studies compare prevalence of drug use among drivers involved in RTCs (i.e. 
cases) with a control group not involved in RTCs. This type of study is often regarded as the 
best epidemiological method to calculate the association between the exposure (substance 
use) and the outcome (crash risk). The crash risk can be expressed as an odds ratio (OR). The 
main advantages of these studies are that drivers in normal road traffic are included and 
that both medicinal and illicit drugs are studied. Confounding factors in such studies might 
be analyses of drugs in different matrixes for cases and the control group (e.g. blood versus 
urine) or different analytical methods, which makes it difficult to directly compare the 
results, and furthermore lack of adjustments for age, sex and time and day of week.    
8.4.1.4. Responsibility studies 
Responsibility studies are also known as culpability studies, and are often classified as a type 
of case-control studies. This type of study was designed to do an assessment of the driver’s 
responsibility in a road traffic accident (65). Drivers involved in a crash are identified as being 
partly or mainly responsible for a RTC (cases) or not responsible (controls). However, it may 
be difficult to determine responsibility, which is the main limitation of these studies. The 
main advantage of these studies is that blood is usually collected from all the drivers and 
drug concentrations in blood are an objective measure of substance use. The concentrations 
can indicate degree of drug impairment. Furthermore, a strength of this study design is that 
real drivers in normal road traffic are studied.  
8.4.2. Measuring driving performance (experimental studies) 
In experimental studies, the effects of psychoactive substances on cognitive and 
psychomotor performance relevant to driving are studied (4). These studies should be 
randomized (when using between-group designs), include a placebo control group, 
administer different doses, and include a so-called benchmark substance, to be able to 
compare to the effects of another drug/treatment (60, 66).  
The literature on traffic safety covers a large number of experimental tests, but there is no 
agreed hierarchy with regard to relative test-importance. An expert group (66) has 
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recommended that validated tests on three core levels of behavior constitute the best basis 
for evaluating whether a certain drug (or dose) represents a traffic risk. The three levels are:  
1) Automative behavior, e.g. tracking and sustained attention;  
2) Control behavior, e.g. skills like overtaking, maintaining distance, divided attention 
and motor performance; and  
3) Executive planning behavior like risk taking and information processing (e.g. 
categorization tasks) 
Furthermore, an expert panel proposed a consensus protocol for assessing drug driving (67). 
Five essential driving ability domains were indicated: (1) alertness/arousal, (2) attention and 
processing speed, (3) reaction time/psychomotor functions, (4) sensory-perceptual 
functioning, and (5) executive functions. The experts stated that “a drug that impairs 
performance in any of these domains at a magnitude known to be associated with increased 
crash risk is presumed to have a negative impact on driving safety”.  
Tests for measuring drug effects on driving-related skills should be supported by theoretical 
models of driving behavior and empirical evidence of their validity (14). Lane keeping and 
passing cars are operations on a maneuver level, and these operations should be performed 
fast and effortless (68). Tests of visual attention, psychomotor function and executive 
control are considered highly relevant to the maneuvering level when assessing impairing 
effects of drugs on driving (69, 70). Many of the studies on non-alcohol drugs lack, however, 
a benchmark substance; the use of an established set of tests sensitive to traffic-related 
effects; or the measurement of drug concentrations in blood and other matrixes (4, 36).  
The main advantages of experimental studies are the low number of participants needed for 
a significant power to detect drug-induced impairment; they allow individual drugs to be 
investigated rather than drug groups; the investigators have full control on doses 
administered; and sensitive and validated tests may be applied (60). 
Main limitations are administration of only low doses, due to ethical reasons (i.e. high doses, 
combined drug use or repeated doses are missing); hangover or withdrawal symptoms after 
repeated or large doses cannot easily be studied; participants know they are being tested 
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(i.e. can thereby possibly compensate for impairment) and the setting might be somehow 
unrealistic; and the performed tests may not be relevant to driving performance (60). 
Another limitation is the possible learning-effects when tests are repeated without training; 
this could bias the results as performance can improve over time. Acute tolerance may 
develop, which means that the impairing effects may be different at the same drug blood 
concentration, when increasing and decreasing. Furthermore, several studies are missing 
assessment of subjective measures (e.g. feeling “high”) as well as subjective assessment on 
fitness to drive (60). This might indicate if the test person is willing to drive after taking the 
substance in a normal setting, even though it has been shown that drivers can poorly predict 
their own driving impairment (71). 
The use of a benchmark substance increases comparability of impairment levels (66). 
Alcohol is well studied and is often used as benchmark substance as a concentration-effect 
relationship has been documented for several tests. A benchmark substance like alcohol can 
therefore provide information on the magnitude of impairment when compared to effects 
and effect sizes of a given drug. Furthermore, concentration-effects of alcohol can 
demonstrate that a test is sensitive and has been undertaken properly (72). 
Both high sensitivity and validity of the tests used in neuropsychological studies are 
important to ensure good quality of the research. The sensitivity of a test is high if it is able 
to detect the impairing effects of a relatively low dose of a psychoactive substance (14). 
Validity is how well a test measures what it intends to measure (73, 74). Validity can refer to 
several aspects of experimental methods, like external validity (the generalizability of the 
results of a test, e.g. how well test subjects represents the general population) (75, 76), 
ecological validity (how representative the findings are of the real world or tasks, e.g. 
whether an on-road driving study generalizes to real-life driving ) (76, 77); face validity 
(whether a test subjectively appears to measure what it actually measures, e.g. does the test 
subjects assess a driving simulator as a naturalistic impression of driving) (76); construct 
validity (the degree to which a test measures what it purports to be measuring, e.g. whether 
neurocognitive tests in a study of drug effects on driving measure driving skills or effects 
relevant to driving) (77); predictive validity (the ability of a measure to predict what it 
theoretically should predict, e.g. whether a driving test or neurocognitive tests actually can 
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predict crash risk in real road traffic) (78); and internal validity (how well a causal 
relationship between a dependent and an independent variable can be tested, e.g. whether 
drug effects are the only possible explanation to the effects observed on driving skills) (76, 
79).  
Psychomotor and cognitive functions relevant for driving can be tested in experimental 
studies using several different methods:  
1) Actual on-road driving;  
2) Simulator driving;  
3) Testing of separate psychomotor functions, e.g. attention and reaction time; and 
4) Testing batteries of several cognitive- and/or psychomotor functions  
8.4.2.1. On-road driving studies 
The on-road driving test was developed in the Netherlands and has been applied in 
psychopharmacological research for more than 30 years (77, 80). It is considered the golden 
standard for measuring drug effects on driving (15, 81). The on-road driving test is 
performed in normal traffic on a public highway and reflects actual driving and associated 
risks. The primary outcome is the standard deviation of lateral position (SDLP) which is a 
measure of the “weaving” of the car or road tracking control, see Figure 4. The test has been 
applied in several studies of alcohol and a large variety of psychoactive drugs such as 
cannabis, MDMA, benzodiazepines, antihistamines and antidepressants, e.g. (81-87), but 
only two studies including opioids have been conducted (31, 88).  
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Figure 4 The standard deviation of lateral position (SDLP) is a measure of tracking error or 
“weaving”. The figure illustrates how the SDLP increases after use of a sedating drug. (by J. 
Ramaekers, 2018) 
 
SDLP was one of the first standardized driving measures for increasing doses of alcohol (81). 
A recent pooled data analysis study stated that BACs of 0.05 % were associated with a mean 
increase of the SDLP of 2.5 cm, which has been defined as the minimal cut-off value to 
represent clinical relevance (81). It has been shown that change in SDLP after alcohol intake 
is strongly correlated to crash risk, indicating that the SDLP shows drug-impairing effects on 
driving and might also predict crash risk (89).  
Main advantages of the on-road driving test are that it measures overall vehicle control, has 
a low learning effect, and test subjects have a high motivation to perform the test. Main 
limitations are the risk of accidents and unexpected incidents, and a long duration of the 
test. Furthermore, the on-road driving test measures road tracking control, a highly 
automated behavior, and thereby to a less extend complex driving skills requiring conscious 
control.  
The on-road driving test has a high external validity which means that the results can be 
applied to a general population and a high ecological validity because it is performed in 
normal traffic and the results can be generalized to real-life settings (14).  
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8.4.2.2. Driving simulator studies 
Driving simulators can be used to perform a computer simulation of a driving task. Simulated 
driving makes it possible to study different types of driving situations, e.g. driving in rural or 
urban areas, during daytime or nighttime, under challenging situations or exposed to 
unexpected events. The main advantages of driving simulators are that the tasks can be 
standardized and the data safely acquired. Main limitations are that driving simulators 
cannot replicate real driving conditions completely, and the subject’s responses and risk 
taking may be different in the simulated driving setting than in real traffic. Furthermore, 
many subjects experience simulator sickness, which can interfere with the results.  
Driving simulators can also be used to measure SDLP and has a high external validity like on-
road driving studies. The increase in SDLP following alcohol intake has been shown to be 
comparable in simulated driving and real driving (90). Furthermore, a dose-response 
relationship was found between higher BAC and increasing SDLP for simulator driving and 
on-road driving on a closed circuit (91). 
8.4.2.3. Neurocognitive tests 
Neurocognitive tests are sensitive to the impairing effects of psychoactive substances and 
can be used to assess potential driving impairment. These tests can never reproduce the 
complexity of driving skills completely, but can provide important information on 
neurocognitive functions essential to safe driving. Many different functions can be tested, 
e.g. attention (divided and sustained), vigilance, tracking, visual functions, reaction time and 
en-/decoding.  
Experimental studies investigating effects of alcohol and drugs on driving and driving-related 
skills have shown that tests of tracking and attention are among the most sensitive tests 
(92). A recent study compared the relative sensitivity of psychomotor tests for three doses 
of alcohol; leading to BACs of 0.02, 0.05 and 0.08 % (92). It was revealed that the Divided 
Attention Task (DAT) was significantly impaired after all alcohol doses compared to placebo. 
The Psychomotor Vigilance Test (PVT) and the Balance Test (PBT) was impaired at BACs of 
0.05 and 0.08 %. The PVT is often applied in sleep research to assess drowsiness following 
sleep deprivation in drivers (92, 93), and DAT and PVT are considered to be considerably 
valid in assessing potential driving impairment. 
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8.5.  Opioids: use, pharmacodynamics and pharmacokinetics 
Opioids are widely used analgesics and regarded as among the most effective drugs for the 
treatment of pain. Opioids are drugs that exert their effects mainly through binding to opioid 
receptors. Opioid receptors are distributed in the brain, the spinal cord, on peripheral 
neurons and the digestive system. Opioids produce analgesia, sedation, respiratory 
depression, suppression of cough, euphoria and constipation, and are potentially addictive. 
Frequent unwanted effects are nausea and vomiting. Acute overdosing can lead to coma and 
respiratory depression and can be fatal. Common for all opioids is that their effects are 
blocked by opioid antagonists such as naloxone. It is known that tolerance develops, 
although to various extents, to many of the effects of opioids (94). 
There are three major subtypes of opioid receptors: Delta (δ)-, kappa (κ)-, and mu (µ)-
receptors (95). Animal studies have shown that mu-opioid receptors (MORs) alone are 
responsible for both therapeutic and adverse actions of morphine (95). Furthermore, MORs 
are the key molecular target for other opioids such as methadone.  
The blood-brain barrier separates the circulating blood from the blood and extracellular fluid 
in the central nervous system (CNS). Only small, lipid-soluble molecules can cross this barrier 
freely. Transport of larger molecules is selective via endocytosis or transcytosis (96). Opioids 
cross the blood-brain barrier by ATP-binding cassette (ABC) transporters (97), while P-
glycoprotein (P-gp) mediates efflux of opioids at the blood-brain barrier. Both methadone 
and buprenorphine are substrates of P-gp (97).  
Large variation in clinical response has been reported for opioid analgesics (98). The reasons 
for the variability are not fully understood, but it has been suggested that allelic variants 
determining the composition of opioid receptor and slight differences in receptor-binding 
profiles between opioids could play a role. Metabolic variability may also influence response 
to opioids in terms of efficacy and tolerability.  
Opioids have large potential for misuse and addiction. High doses may have euphoric effects, 
which after repeated use may cause craving, and development of tolerances causes the user 
to steadily increase the doses. Opioid misuse is the most common cause of drug-related 
deaths (99-102), but the preferred substances may differ between countries. In Norway, 
heroin used to be the most commonly drug causing fatal overdoses, but in recent years the 
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number of methadone and buprenorphine related fatalities have increased (99). 
Buprenorphine is at present the most commonly used opioid by people who inject drugs in 
Finland (103), while methadone is the most common cause of overdoses in Denmark (104). 
Other countries have experienced serious problems with overdoses by fentanyl or 
oxycodone (101, 105). At present, misuse of the latter two substances does not constitute a 
serious problem in Norway.  
8.5.1. Opioid-maintenance treatment (OMT) 
OMT is a long-term intervention attempting to stabilize and rehabilitate persons with heroin 
addiction. The substitute drugs used in OMT are mainly methadone or buprenorphine. The 
OMT medications have long half-lives and prevent withdrawal symptoms and reduce 
cravings. A total of 628,000 persons received opioid substitution treatment in Europe in 
2016 (106), while 7,622 patients received OMT with either methadone or buprenorphine in 
Norway at the end of 2017 (107).  
The main aim of rehabilitation with OMT is to return to daily life activities. If daily doses are 
stable and there is not abuse of other psychoactive drugs, there is a possibility to be able to 
drive a car. Driving might be pivotal to be able to return to work, maintain relationships and 
participate in activities. Regulations to permit driving under OMT vary between European 
countries: in most countries driving during treatment is permitted, but in some countries, 
like the Netherlands, Lithuania and Slovakia, driving during OMT is prohibited (108). 
However, restrictions related to driving by OMT patients are often justified by public 
interests, like traffic safety. Drivers with limited driving skills and/or who pose an increased 
risk of road traffic crashes are prevented from driving, like persons driving under the 
influence of psychoactive substances. 
In Norway it is permitted to drive during OMT if the following requirements are met:  
− treatment under proper supervision and follow up by a known physician;  
− stable dose for a minimum of 1 year;  
− and no use of sedative or illicit drugs, the latter for a minimum of 1 year.   
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While it is well known that the combination of two or more psychoactive drugs significantly 
increases the risk of serious or fatal injury in traffic (109), the time to develop tolerance to 
the impairing effects of methadone and buprenorphine is not well studied.  
A reduction in convictions for DUI among Norwegian OMT patients in treatment as 
compared to pre-treatment has been shown (110).  During treatment a reduction of almost 
40 % was seen, indicating that OMT is an effective tool to reduce convictions for DUI among 
opioid-dependent persons.  
8.5.2. Methadone 
Methadone is a full synthetic, long-acting opioid, primarily used in OMT of persons with 
heroin addiction. It is, world-wide, the most frequently prescribed drug with this indication 
(41, 111). Methadone is also widely used as an analgesic. Methadone was developed in 
Germany during World War II as a morphine substitute (112), see Figure 5 for chemical 
structure. It was approved for use in the USA in 1947.  
 
Figure 5 Molecular structure of methadone (Source: Wikipedia, no “fair use” file) 
 
Methadone can be administered per oral as tablets or mixture, or parenteral via injections 
e.g. epidurally or intravenously. Methadone can be detected in blood 15–45 minutes after 
oral administration, with average peak plasma concentrations at 2.5–4 hours. An up to 17-
fold inter-individual variation has been reported for methadone concentrations in blood 
after a given dose (113). The oral bioavailability averages 85 % (114), but a wide variation 
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has been observed with a range of 36–100 % (113). Methadone is highly bound to plasma 
proteins and a mean free fraction of 10–14 % has been measured (113). Methadone has a 
long half-life of 24–60 hours (115). Methadone and morphine are approximately equipotent 
as analgesics when taken parentally, but as a result of drug accumulation, methadone 
produces marked sedative effects with repeated administration (112). Administration of 
methadone, being an agonist with strong affinity to the µ-receptor, increases the effects of 
other opioids being present at the same time. Methadone displays large inter-individual 
variability in its pharmacokinetics (113) and apparently also in its pharmacodynamics. 
A regular dose of methadone in pain treatment is 5–10 mg per oral 3–4 times per day. A 
regular dose of methadone in maintenance treatment is between 60–130 mg/day, and is 
usually administered as a solution. In opioid-naïve patients, the recommended starting dose 
is 2.5 mg every 8–12 h with a dose increase by 2.5–5 mg increments every 5–7 days. A single 
dose of 10 mg methadone per oral produced an average peak blood concentration of 34 
ng/mL in healthy men (114). For opioid-tolerant patients, an appropriate methadone-to-
morphine conversion ratio ranges from 1:5 to 1:20 (115). It is not recommended to initiate 
treatment with methadone in doses higher than 30 mg per day in any patient (115). Doses of 
50 mg or less have been reported to cause fatalities in nontolerant adults (112). 
The pharmacological activity is mainly due to the active stereoisomer levomethadone, also 
known as (R)-methadone (112). Racemic methadone contains both (R)-methadone and the 
dextrorotatory (S)-methadone isomer in a 50/50 mixture. Methadone is metabolized to 2-
ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) mainly by Cytochrome P450 
(CYP2B6) (116, 117). CYP2B6 expression can influence the concentration of methadone in 
blood. Poor metabolizers (CYP2B6*6/*6 carriers) are shown to have higher concentrations of 
methadone in blood after intake (118). A recent study found that patients homozygous for 
CYP2B6*6 had a 90 % higher methadone serum concentration/dose (C/D) ratio (119). 
CYP2B6 polymorphism can be tested by genotyping.  
Long-term treatment with high doses of methadone is associated with QTc interval (interval 
between Q wave and T wave of the heart’s electrical cycle) prolongation, arrhythmia and 
sudden death (120). The use of electrocardiography screening prior to methadone treatment 
has therefore been recommended in Norway (121).  
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8.5.3. Buprenorphine 
Buprenorphine is a partial opioid agonist/antagonist and semi-synthetic opioid which binds 
to µ- and κ-receptors in the brain, see Figure 6 for molecular structure. Buprenorphine has 
been introduced as an alternative to methadone in maintenance therapy (122), but is also 
widely used as an analgesic. The effect of maintenance treatment with buprenorphine is 
possibly attributed to the slow reversible binding to µ-receptors. Buprenorphine has a wide 
therapeutic range due to its agonist/antagonist effects, which limits its depressant effects 
especially on respiratory and cardiac functions (123). Buprenorphine was manufactured as 
an injection in the UK from 1978 to treat severe pain. The sublingual formulation was sold 
from 1982.  
 
 
Figure 6 Molecular structure of buprenorphine (Source: Wikipedia, no “fair use” file) 
 
Buprenorphine undergoes extensive first-pass metabolism and has a low bioavailability 
when administered orally (only 10 % of the intravenous route) (124). Buprenorphine is 
administered parenteral either sublingual, transdermal or via injections e.g. intravenously or 
intramuscularly. The bioavailability after sublingual administration is 30-50 % of the 
intravenous route (124). Average peak plasma concentrations after sublingual intake have 
been reported at 0.8–1.3 hours (112) and ranging from 40 minutes to 3.5 hours (125). Linear 
relation between concentrations of buprenorphine in plasma and doses (ranging from 1–32 
mg sublingual) has been shown in non-dependent subjects (126). Buprenorphine is highly 
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protein bound (96 %) and has a large volume of distribution (125). Buprenorphine readily 
crosses the blood-brain-barrier, and crosses the placenta during pregnancy and also into 
breast milk (125). 
A regular dose of buprenorphine in pain treatment is 0.2–0.4 mg sublingual up to 3–4 times 
daily. A regular dose of buprenorphine in maintenance treatment is between 8–16 mg/day 
sublingual. Single doses of sublingual buprenorphine to healthy subjects produced the 
following peak blood buprenorphine concentrations: 1.6 ng/mL after 2 mg (127), 3.3 ng/mL 
after 4 mg (128) and 5.8 ng/mL after 8 mg (129).  
Buprenorphine is metabolized to conjugated buprenorphine and norbuprenorphine (an 
active metabolite), mainly by uridine 5’-diphospho-glucuronosyltransferase (UGT1A3) and 
CYP3A4. There is no known polymorphism of these enzymes and therefore genotyping is not 
relevant. However, a number of drugs inhibits and induces CYP3A4 which can affect 
buprenorphine metabolism, e.g. erythromycin inhibits 3A4, while carbamazepine and 
phenytoin induces 3A4. 
8.6.  Current knowledge gaps 
The association between traffic crash risk and the use of methadone and buprenorphine is 
poorly documented. No comprehensive review on the effects of buprenorphine and 
methadone on cognitive and psychomotor task performances had been published; a 
systematic review was therefore required. Few experimental studies on buprenorphine and 
methadone of relevance to road traffic safety had been performed; none included on-road 
driving. More relevant and better designed studies were therefore needed in order to assess 
the effects of those opioids on the ability to drive safely. 
  
26 
 
  
27 
 
9. Aims  
 
The overall aim of this thesis was to provide more knowledge about the impairing effects of 
methadone and buprenorphine in relation to driving.  
The specific aims of the thesis were: 
- To summarize the current knowledge regarding crash risk and impairing effects on 
driving after administration of methadone and buprenorphine (Paper I) 
- To investigate whether methadone and buprenorphine cause traffic relevant 
impairment using an on-road driving test and neurocognitive tests (Paper II) 
- To investigate if there is a dose- and/or concentration-effect relationship for 
methadone and buprenorphine (Papers II and III) 
- To investigate the pharmacokinetic properties of methadone and buprenorphine in 
blood and oral fluid (Paper III) 
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10. Materials and methods 
10.1. A systematic literature review 
Our institute was invited to participate in the European DRUID project in 2006 (130). One 
of the tasks assigned was to conduct a systematic literature search of the current scientific 
literature on the treatment with methadone or buprenorphine related to the effects on 
cognitive- and psychomotor functions relevant to driving in experimental studies, including 
epidemiological studies of patients receiving maintenance treatment with either methadone 
or buprenorphine. 
10.1.1. Search strategy 
Searches were conducted in the databases MEDLINE, EMBASE, and PsycINFO. Searches for 
experimental studies were conducted throughout the month of March of 2010, and searches 
for epidemiological studies were conducted throughout the month of June of 2010.  
The following search words were used for the epidemiological studies: Accident 
involvement; accident risk; car accident; car driver; car driving; case control; cohort; crash; 
culpability; driver; driving ability; driving accident; driving performance; driving skills; 
epidemiology; fatal; highway safety; injured; killed; odds ratio; pharmacoepidemiology; 
relative risk; road safety; roadside survey; traffic accident; traffic safety; and vehicle.  
For the experimental studies the following search words were used: Aggression; aggressive 
behavior; attention; automobile driving; cognition; cognitive function; cognitive process; 
driving ability; error detection; hypnotics and sedatives; impulsive behavior; impulsivity; 
judgment; memory; motor skills; psychomotor effect; psychomotor impairment; 
psychomotor performance; sedation; sedatives; steering; tracking; vigilance; and visual 
perception.  
To retrieve as much relevant literature as possible the defined words were searched using 
two separate methods: 1) As controlled vocabulary (i.e. using own vocabulary/thesaurus of 
the databases); and 2) As free text words (key words). To broaden the search the relevant 
words were combined with the Boolean operator ‘OR’. The result was then limited to one of 
the following types of studies: Experimental, quasi-experimental and controlled. No limits 
were made as to publication year or publication language. Finally, the search strategy was 
combined with the words methadone, levomethadone, and/or buprenorphine. 
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Epidemiological studies containing risk analysis were included in the review. In addition, 
several articles, including a number of reviews, were screened as sources of reference for 
the primary research literature. 
Inclusion criteria for the experimental studies were: performed in humans only; subjects had 
to be either patients in maintenance therapy, opioid-dependent abusers (current drug 
abuse), or healthy volunteers (with no known history of drug abuse); reported drug 
concentrations and/or doses; including a control group (placebo and/or no drug/baseline); 
measuring objective effects (drug use while driving and/or performing tasks relevant to 
driving); a minimum of 5 participants; and the study had to be published in a scientific 
journal.  
The primary search included about 1,750 titles; approximately 1,500 titles of experimental 
studies and approximately 250 titles of epidemiological studies, see Figure 7. Full-text 
articles of experimental studies were selected from the primary search by one medical 
expert based on the inclusion criteria. The selected articles, consisting of approximately 100 
experimental studies, were evaluated by two medical experts, who selected the final articles 
according to the same inclusion criteria. In addition, approximately 250 epidemiological 
titles with abstracts were retrieved from the primary search and assessed by one medical 
expert. The selected full-text articles, consisting of approximately 40 epidemiological studies, 
were finally assessed by two medical experts. Finally, 59 articles were included in the review; 
54 experimental studies and 5 epidemiological studies. 
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Figure 7 Flow-chart showing the process of the literature search of experimental studies and 
epidemiological studies on methadone and buprenorphine, and the number of articles 
retrieved at the different stages of the search. 
 
10.2. A clinical on-road driving study 
We conducted a placebo controlled study on the impact of buprenorphine and methadone 
on on-road driving and cognitive performance. All tests were validated and represented all 
levels of behaviors as recommended for drug d riving research; (1) automative behavior, (2) 
control behavior, and (3) executive planning behavior (66), see chapter 8.4.2.  
Healthy volunteers with significant driving experience were recruited through local 
advertisements and participants were included after a medical screening. After inclusion the 
participants performed a training session for the driving test and the computer tests. The 
volunteers participated in five study days each. A timeline of the test day is shown in Figure 
8. 
Primary search 
Experimental studies 
Approximately 1,500 titles with 
abstracts  
100 full-text articles 
54 experimental studies 
Articles selected 
according to the same 
criteria by 2 experts 
Articles selected 
according to defined 
criteria by one expert 
Epidemiological studies 
Approximately 250 titles with abstracts 
40 full-text articles 
5 epidemiological 
studies 
Articles selected 
according to the same 
criteria by 2 experts 
Articles selected 
according to defined 
critera by one expert 
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Figure 8 The timeline of a test day (from Paper II). 
 
10.2.1. Procedure for the clinical study 
On arrival, urine was screened for drugs (methamphetamine, cocaine, THC, morphine, 
benzodiazepines and amphetamine), a pregnancy test was performed, and breath alcohol 
was analyzed. Participants were asked to refrain from consuming caffeine on test days and 
alcohol intake 24 hours prior to test days. The Groningen Subjective Quality of Sleep 
Questionnaire was used to assess sleep quality the night before test days.  
 
Blood and oral fluid were collected throughout the test day. The on-road driving test was 
performed 4 hours after treatment administration. Before and after the driving test, i.e., 2.5 
and 5.5 hours after treatment intake, participants performed two sessions of laboratory 
testing (i.e. morning and afternoon session). Each session consisted of the PVT, the Critical 
Tracking Task (CTT), the DAT, the Digit Symbol Substitution Test (DSST), the Useful Field of 
View Test (UFOV), the PBT, and the Vienna Test System – Determination Test (DT/S1). Two 
sessions were performed to see how the blood drug concentrations and effects changed 
over time, and also to take acute tolerance into account. Before the driving test, a 
standardized light lunch was served. After completion of a test day, participants were 
transported home by a driving instructor. 
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10.2.2. Subjects 
Twenty-two healthy volunteers (11 males, 11 females) were included after screening of 29 
volunteers in total. Three subjects were excluded based on the exclusion criteria (prolonged 
QT-interval, CYP2B6 poor metabolism and high drug abuse potential) and the remaining six 
were “drop outs” (e.g. due to lack of time to participate or personal circumstances). The 
volunteers were 23–49 years old with a mean age of 36 years. None of the volunteers used 
opioid analgesics regularly at the time of testing.  
In order to be eligible to participate in the study, each participant had to meet all of the 
following inclusion criteria:  
- Healthy males or females, in the opinion of the medical supervisor, based on a 
physical examination, medical history, vital signs, electrocardiogram, and the results 
of blood chemistry and hematology tests, and urine analysis  
- Aged between 23 and 50 years 
- Body mass index (weight/length2) between 19 and 29 m2/kg 
- Possession of a valid driving license for 4 years or more 
- Driving experience of at least 5,000 km per year on average  
- Good sleeper 
 
Subjects who meet any of the following criteria were excluded from participation in the 
study:  
- Sleep disorders such as insomnia and narcolepsy 
- History of or current drug or alcohol abuse 
- Current use of psycho-active medication, and inability to stay abstinent during the 
study 
- Excessive alcohol use, defined as drinking more than 14 (females) / 21 (males) units 
of alcohol per week 
- Excessive caffeine use, defined as drinking 5 or more cups of coffee per day 
- Smoking more than 10 cigarettes per day 
- History or presence of drug/alcohol abuse, including experience with heroin, 
methadone and buprenorphine 
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- Intake of any opioid within 3 months before the study 
- Use of any drug that is considered to influence the test drugs, including trade 
herbal products 
- History of severe allergic disease 
- History of significant mental, cardiovascular, renal or hepatic disorder, or other 
significant disease as judged by the investigator 
- Positive pre-session urine sample of any of the following substances: ethanol, 
benzodiazepines, tetrahydrocannabinol, cocaine, amphetamines or opioids 
- Poor metabolism due to CYP2B6 polymorphism 
- Prolonged QT-interval (history of or presence at screening) 
- Use of any drug that is known to inhibit or induce CYP3A4 activity 
- Women who are pregnant or breastfeeding  
- No use of a reliable contraceptive 
 
All volunteers had to sign an Informed Consent Form at the time of the screening. 
Absence of drug abuse or drug abusing potential was important. Each volunteer was 
screened with regards to drug abuse using the Alcohol Use Disorders Identification Test 
(AUDIT) and the Drug Use Disorders Identification Test (the DUDIT). Each participant also 
had to test negative for drugs and alcohol during screening and on test days. 
There is reason to believe that in several of the drug driving cases where the driver tests 
positive for methadone or buprenorphine, neither of the drugs are prescribed. The test 
subjects in the current clinical study could therefore represent persons outside maintenance 
treatment with recreational (and occasional) use of these drugs, as well as drug-naïve 
persons receiving these drugs in relation to pain treatment.  
10.2.3. Drug doses  
On each test day participants received two capsules containing methadone or placebo and 
two sublingual tablets containing buprenorphine or placebo, according to a double-dummy 
procedure. 
Methadone 5 mg, methadone 10 mg, buprenorphine 0.2 mg, buprenorphine 0.4 mg and 
placebo were administered in a randomized order. Methadone and buprenorphine doses of 
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the same magnitude have been administered to opioid-naïve users in previous studies (131-
134). The dose of methadone frequently used for pain relief is 10 mg per oral 3 times daily 
(135). Temgesic® (buprenorphine) is used in pain treatment in doses of 0.2-0.4 mg sublingual 
up to 3–4 times daily (136). A single dose of buprenorphine 0.8 mg sublingual is equivalent 
to morphine 60 mg per oral, while a single dose of methadone 20 mg per oral is equivalent 
to morphine 60 mg per oral (137). These doses are considered equivalent with regards to 
analgesic effects.  
Methadone was administered as capsules while buprenorphine was administered as 
sublingual tablets. Methadone (methadone capsules and placebo capsules) and 
buprenorphine (buprenorphine sublingual tablets and placebo sublingual tablets) were 
purchased, blinded and labelled by the University Pharmacy of Nijmegen (the Netherlands) 
and Tiofarma (Oud-Beijerland, the Netherlands), respectively, according to the Good 
Manufacturing Practice guidelines. The tablet containers are shown in Figure 9.  
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Figure 9 The packaging of the methadone capsules and the buprenorphine tablets before 
blinding. The tablet containers were masked to hide the information regarding the content. 
One set of two containers identical to the ones on the photo, containing two capsules and 
two tablets, respectively, were used for each subject on each test day. (Photo: M. Strand 
2016) 
 
10.2.4. Actual Driving Performance (On-Road Highway Driving Test) 
In the On-Road Highway Driving Test (80) the subjects operate a specially instrumented car 
over a 100 km primary highway circuit maintaining a constant speed (95 km/h) and a 
steady lateral position between the delineated boundaries of the right (slower) traffic 
lane, see Figure 4. An electro-optical device mounted at the back of the car continuously 
measures lateral distance separating the vehicle and the left lane-line, see Figure 10 and 
Figure 11. This signal is stored on an on-board computer disk file for later editing and 
analysis. The offline editing routine involved removal of all data segments that revealed 
signal loss, disturbance, or occurrence of overtaking maneuvers, see Figure 13. The 
remaining data are then used to calculate means and variances for lateral position and 
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speed. SDLP (in centimeters) is taken as the primary outcome variable, see Figure 4. SDLP is 
a measure of road tracking error; in practical terms, it is a composite index of allowed 
weaving, swerving, and overcorrecting. The test duration is approximately one hour. 
 
  
Figure 10 Two of the test cars parked outside the Maastricht University. (Photo: M. Strand 
2016) 
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Figure 11 The tube containing the camera measuring the distance to the lane line or the 
edge line during the highway driving is attached to a car top carrier on the automobile roof. 
(Photo: H. Gjerde 2016) 
 
 
 
Figure 12 Professor Mørland driving one of the test cars, assisted by Professor Ramaekers, 
on the test circuit on Highway A2 from Maastricht. (Photo: H. Gjerde 2016) 
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Figure 13 The data from the on-road driving test was manually edited to remove the 
sections of overtake, turn around, too low velocity and disturbances on the signal caused by 
reflections. (Screenshot from editing by M. Strand 2017) 
 
10.2.5. Selected performance Tests 
The selected neurocognitive tests have shown in previous studies to be sensitive to 
impairing effects of psychoactive substances (14, 93).  
10.2.5.1.  Critical Tracking Task (CTT) 
The CTT measured the ability to control an unstable error signal in a first-order 
compensatory tracking task (138), see Figure 14. This test is designed to measure 
psychomotor (eye-hand) coordination. Tracking skills are especially important at the 
operational/control level of driving behavior (e.g., keeping the car in a steady position 
within the lane). Subjects are instructed to keep an unstable bar in the middle of a 
horizontal plane by counteracting or reverse its movements with the aid of a joystick. 
The frequency of cursor deviations at which the subject loses control is the critical 
frequency. The test comprises five trials. The final score (in rad/s) was determined from 
the average of all but the lowest and the highest scores in five trials. The test duration was 
approximately 3 minutes. 
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Figure 14 Dr. Vindenes performing the Critical Tracking Task using a joystick to balance the 
yellow triangle between the green bars on the screen. The test measures psychomotor 
coordination and is a test of automative behaviour. (Photo: H. Gjerde 2016)  
 
10.2.5.2. Divided Attention Task (DAT) 
The DAT measured the ability to divide attention between two simultaneously performed 
tasks (139). In the primary task, the subject performed the same tracking task described 
above (CTT), yet at a constant level of difficulty set at 50 % of the participant’s maximum 
capacity. In the secondary task, the subject monitored 24 peripheral displays in which 
single digits changed asynchronously at 5-s intervals. Subjects were instructed to remove 
their foot from a pedal as rapidly as possible whenever the digit “2” appeared. This 
signal occurred twice at every location, in random order, at intervals of 5–25 s. Tracking 
error (DAT-ER, in mm) and average reaction time to targets (DAT-RT, in milliseconds), 
control losses, hits, misses and false alarms were the respective performance measures. The 
test duration was approximately 20 minutes. Figure 15 shows two volunteers performing the 
DAT simultaneously in two separate test rooms. 
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Figure 15 Two participants being monitored while performing the DAT in two separate 
rooms. The test measures the ability to divide attention between two simultaneously 
performed tasks and is a test of control behavior. (Photo: H. Gjerde 2016) 
 
10.2.5.3. Psychomotor vigilance task (PVT) 
The (PVT) measured sustained vigilant attention by assessing the reaction time in response 
to a visual stimulus (140). The visual stimulus came from a counter in the center of a 
computer screen running at random intervals between 2 and 10 s. The subject had to react 
to the onset of the counter as quickly as possible by pressing a response button, see Figure 
16. Duration of the task was 10 minutes. This task has often been used to assess the impact 
of sleep loss on performance.  
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Figure 16 Dr. Vindenes performing the PVT, which measures sustained vigilant attention by 
assessing the reaction time in response to a visual stimulus and is a test of automative 
behavior. (Photo: H. Gjerde 2016)   
 
10.2.5.4. Digit Symbol Substitution Test ( D S S T )  
The DSST (141) measured executive attention and processing speed, and is a test of 
recognition. A computerized version of the original paper-and-pencil test taken from the 
Wechsler Adult Intelligence Scale was used (142). The subject was shown briefly an 
encoding scheme consisting of a row of squares at the top of the screen, wherein nine 
digits were associated randomly with particular symbols. The same symbols were presented 
in a fixed sequence at the bottom of the screen as a row of separate response buttons. The 
encoding scheme and the response buttons remain visible while the subject was shown 
successive presentations of a single digit at the center of the screen. The subject was 
required to match each digit with a symbol from the encoding list as rapidly as possible 
by clicking the corresponding response button, using the mouse, see Figure 17. The 
number of digits encoded correctly and in total, respectively, within 3 min were the 
performance measures. 
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Figure 17 Dr. Vindenes performing a computerized version of the DSST. The DSST measures 
executive attention and processing speed and is a test of executive planning behavior. 
(Photo: H. Gjerde 2016)  
 
10.2.5.5. Balance Test (PBT) 
Balance was measured using the AMTI AccuSway System for Balance and Postural Sway 
Measurement (Advanced Mechanical Technology, Inc., Watertown, MA, USA) force 
platform (143, 144). Postural sway is a test of how much you move when trying to stand still 
and was assessed by measuring the length of the path of the centre-of-pressure (COP), and 
the area of the 95 % confidence ellipse enclosing the COP (A95), see Figure 18. The test 
was conducted in two trials: one trial with the subjects' eyes open and one trial with eyes 
closed, both with feet apart at hip's width. The test duration was 60 seconds for each trial. 
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Figure 18 The PBT test measuring the centre-of-pressure (COP) in the placebo morning 
condition with eyes closed (left panel) and buprenorphine 0.4 mg morning condition with 
eyes closed (right panel) of subject 9. Postural sway is a test of how much you move when 
trying to stand still and the figure shows that the subject is swaying more in the drug 
condition as indicated by the red line. PBT is a test of automative behavior. 
 
10.2.5.6. Useful Field of View (UFOV) 
The UFOV (145) was tested by using a computerized version with mouse including three 
increasingly difficult, visually presented subtests: stimulus identification, divided attention, 
and selective attention, see Figure 19. The first subtest, which measured processing speed 
under the lowest demand conditions, required participants to identify a target presented 
at a central fixation point on the screen. The target (silhouette of a 2 cm by 1.5 cm truck or 
car) was presented on a black background in a 3 cm × 3 cm fixation box. The second subtest, 
which measured processing speed for a divided attention task, involved identification of 
this central target along with localization of a simultaneous peripheral target (2 cm × 1.5 
cm silhouette of a car) presented at one of 8 radial locations. The third subtest, which 
measured processing speed for a selective attention task, included these two tasks, but also 
included visual distractors (triangles of the same size and luminance as the targets) arranged 
in concentric circles around the peripheral target. Each trial consisted of four display 
screens: 1) a fixation box, 2) a test stimulus, 3) a full-field, white-noise visual mask, and 4) 
a response screen. The white noise visual mask was presented following the stimuli in 
order to control display duration and to eliminate after images. Measures registered were 
total detection time per task (1-3) and total detection time all. 
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Figure 19 UFOV is a test measuring executive planning behavior. The upper panel shows the 
first subtest: stimulus identification. The middle panel shows the second subtest: divided 
attention. The lower panel shows the third subtest: selective attention. Used with 
permission: Oxford University Press. 
 
10.2.5.7. Determination test (DT/S1) 
This test was used to measure ‘resilience of attention and reaction speed under conditions 
of sensory stress’. The task of the respondent was to identify various stimuli and to react 
to them by pressing the respective corresponding response buttons, using the response 
panel of the Vienna Test System, see Figure 20. The test was administered as a 
computerized adaptive test whereby the presentation time of the stimuli adjusts itself to the 
reaction speed of the respondent. However, unlike classic computerized adaptive tests, this 
test form presents the stimuli a little faster than would be optimal given the respondents’ 
reaction speed, thus resulting in a condition of sensory stress. Measures registered were 
median reaction time and number correct. 
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Figure 20 Dr. Vindenes performing the Determination test (DT/S1) which measures resilience 
of attention and reaction speed under conditions of sensory stress and is a test of 
executive planning behavior. (Photo: H. Gjerde 2016)  
 
10.2.5.8. Simplified clinical test of impairment (SCTI) 
The clinical test of impairment (CTI) used by the police in DUI cases in Norway consists of 25 
tests and observations related to common signs of drug impairment. Examples are: memory, 
eyes (pupils, nystagmus, convergence-insufficiency), balance and motor coordination, 
cognitive function, alertness and appearance (146). After conducting all tests, the physician 
concludes whether the person is not impaired, lightly impaired, moderately impaired, 
severely impaired or that it is not possible to make a conclusion. These tests are used in 
Norway by doctors working for the police with suspects driving under the influence of drugs.  
Five subtests from the Norwegian CTI were selected: gait-on-line test, turn-on-line test, 
finger-to-finger test, finger-to-nose test, and Romberg’s test (standing steady on one leg for 
at least 5 s with arms stretched out and eyes closed) (147). For each of the five subtests, the 
performance was measured and scored as either ‘‘habitual’’, ‘‘somewhat deviant’’, or 
‘‘deviant’’. The overall impression of the subject, being the sixth subtest, was graded as 
either ‘‘not impaired’’, ‘‘slightly impaired’’ or ‘‘moderately impaired’’. The volunteers were 
assessed approximately 1.5 h after drug intake on each study day. 
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10.2.6. Subjective rating scales 
10.2.6.1. Mood Rating Scale (Bond and Lader) 
Subjective evaluations of mood and apparent sedation were assessed by using a series of 
visual analogue scales (100 mm) (63). Subjects rated their subjective feelings on a 16-item 
mood scale which provided three factor analytically defined summary scores for ‘alertness’, 
‘contentedness’, and ‘calmness’.  
10.2.6.2. The Karolinska sleepiness scale (KSS) 
The KSS is a subjective rating scale with scores that range from 1, “extremely alert,” to 9, 
“very sleepy, great effort to keep alert, fighting sleep” (62). Participants are instructed to 
report their experienced sleepiness during the preceding 10 min. Reyner and Horne 
modified the original scale by adding verbal descriptions to intermediate steps, which do not 
have any descriptions in the original version (75). The modified scale was used in our study. 
10.2.6.3. Groningen Subjective Quality of Sleep Questionnaire 
The Groningen Subjective Quality of Sleep questionnaire (76) was filled out at the beginning 
of a test session to assess the subject’s sleep quality and sleep duration of the previous 
night. This questionnaire scored sleep complaints, ranging from 0 (good sleep) to 14 (bad 
sleep). The participant could proceed to drug administration and testing with a score ≤ 6. 
10.2.7. Drug analyses 
The blood and oral fluid samples were collected by trained personnel and stored in a freezer 
within 15 minutes after sampling. Eventually, all samples were transported on dry ice from 
Maastricht to Oslo for analyses. 
10.2.7.1. Blood 
Four blood samples were collected during each test day, see Figure 8, using 5-ml Vacutainer® 
tubes containing sodium fluoride (20 mg) and sodium heparin (143 IU). Concentrations of 
methadone and buprenorphine in whole blood were determined by ultra-high-performance 
liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) (148); the method was 
slightly modified for the determination of methadone and buprenorphine by adding relevant 
calibration standards.  
The limit of quantification (LOQ) in blood (defined as the lowest concentration complying 
with a precision RSD of 15%) was 0.15 ng/mL for methadone and 0.09 ng/mL for 
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buprenorphine, whereas the limit of detection (LOD) was 0.05 ng/mL for methadone and 
0.009 ng/mL for buprenorphine.  
10.2.7.2. Oral fluid 
Five oral fluid samples were collected during each test day, see Figure 8, using the Quantisal 
Oral Fluid Collection Device, which was supposed to collect about 1 ml of oral fluid to be 
diluted with 3 ml preservation buffer present in the collection device. Drug concentrations in 
oral fluid-buffer mixtures were determined using ultrahigh-performance liquid 
chromatography-tandem mass spectrometry (UHPLC-MS/MS) after 96-well supported liquid 
extraction (149).  
All samples were weighed to determine the amount of oral fluid collected (assuming that 
1.00 mL weighs 1.00 g), and concentrations in neat oral fluid were calculated. This calculation 
was done by multiplying the concentration in oral fluid (ng/mL) by the oral fluid volume (mL) 
+ 3 mL (amount of buffer) and dividing this by the oral fluid volume (mL). 
The LOQ in neat oral fluid was 0.31 ng/mL for methadone and 0.47 ng/mL for buprenorphine, 
whereas the LOD was 0.046 ng/mL for methadone and 0.07 ng/mL for buprenorphine.  
10.2.8. Statistics 
10.2.8.1. Sample size 
An a priori statistical power analysis using G*power 3 (150) showed that in order to detect 
effects of f = 0.25 of the within subject variable (SDLP) a total of 20 participants would be 
adequate, using a two-sided t-test with 95 % power at a significance level of 5 %. This was 
based on a retest reliability of at least 0.70 as found for unmedicated healthy young and 
middle-aged participants in previous studies, and an estimated mean increase of 2.4 cm in 
SDLP on driving performance of social drinkers while their blood alcohol level was 0.5 mg/ml 
in a study by Louwerens and colleagues (16). For balancing purposes, we aimed to include 25 
participants. 
In addition, we expected a drop-out rate of approximately 10 %, which meant that 
approximately 2 participants might drop-out during screening. Therefore, we needed to 
recruit a minimum of 27 participants, preferably an equal number of men and women. We 
continued inclusion until enough participants were included, and eventually ended up with 
11 men and 11 women. 
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10.2.8.2. Methods to test relationship between measurements 
All analyses were conducted using SPSS® Statistics version 25 (IBM Corporation, Armonk, NY, 
USA). 
10.2.8.2.1. Paper II 
Descriptive statistics for pharmacodynamic and pharmacokinetic parameters included n, 
mean, and standard error or standard deviation. Statistical summaries were presented by 
the different conditions (methadone 5 mg, methadone 10 mg, buprenorphine 0.2 mg, 
buprenorphine 0.4 mg and placebo). 
All measures (i.e. the on-road driving test (including SDLP); the neurocognitive tests; the 
simplified clinical test of impairment; and the subjective measures) were analyzed and 
compared between methadone 5 mg, methadone 10 mg, buprenorphine 0.2 mg, 
buprenorphine 0.4 mg and placebo. We were interested in the drug effects within subjects, 
and not between groups. The global model used was the analysis of variance (ANOVA), i.e. 
General Linear Model (GLM) – Univariate Measures. This model included two fixed factors, 
i.e. the factor Treatment (five levels) and the factor Time (two levels), and a random factor 
for Subject. This analysis was followed by an analysis of the main effect of treatment, 
separate contrasts between drug treatments and placebo, and a low dose vs. high dose 
contrast for each opioid.  Additionally, a non-inferiority analysis was performed on the SDLP 
data to determine clinical relevance of drug-induced changes relative to placebo. Non-
inferiority was concluded if the upper limit of the 95 % CI of the mean difference between 
drug and placebo was < 2.5 cm. A mean change in SDLP of 2.5 cm represents a clinically 
relevant level comparable to that of a BAC of 0.05 %. 
10.2.8.2.2. Paper III 
Bivariate correlations were used to evaluate associations between opioid concentrations in 
blood and opioid-induced changes in driving and neurocognitive performance 
(concentration in blood x performance) relative to placebo. The assumption was a linear 
concentration-effect relationship. The concentrations measured 3.5 hours after 
administration were used to calculate correlation with the driving test. The concentrations 
measured after 2 and 6.5 hours were used to calculate correlation with the neurocognitive 
tests and subjective evaluations performed in the morning and afternoon sessions, 
respectively. Correlations were calculated separately for the morning and afternoon sessions 
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to take into account if acute tolerance was developed. To calculate drug-induced change 
relative to placebo, performance scores during placebo were subtracted from performance 
scores during methadone and buprenorphine treatment, respectively. Because few 
correlations were found between drug-induced change in performance and drug 
concentrations in blood, no such calculations were done for oral fluid.  
Concentrations of buprenorphine in blood below the LOQ and above the LOD, see also 
chapter 10.2.7.1, were included when calculating the correlation between drug-induced 
change in performance and opioid concentrations in blood. Only drug concentrations above 
the LOQ were used to calculate oral fluid/blood ratios.  
10.2.9. Ethical considerations 
There were several ethical considerations with regards to our clinical study. Potential serious 
effects are triggering a potential drug abuse in the volunteers causing potential severe side 
effects from the tested drugs and the risk of traffic crashes during testing.   
Methadone and buprenorphine are potent drugs with an addiction risk. Absence of any drug 
abuse or drug abusing potential in the participants prior to the study was important. Each 
volunteer was screened with regards to drug abuse using the AUDIT (the Alcohol Use 
Disorders Identification Test) and the DUDIT (the Drug Use Disorders Identification Test), and 
urine drug screening was used to test for the presence of drugs.  
Many persons may have a negative impression of these drugs, and methadone in particular, 
relating it to heroin abuse and addiction and to heavy drug users. It was important that the 
written information was provided in a clear and very understandable manner and that all 
aspects and risks of the study were described. 
Regarding risk assessment, the volunteers received relatively low doses of methadone and 
buprenorphine similar to the doses administered to opioid-naïve subjects in previous 
studies. The doses were also in the range of doses given to opioid-naïve subjects for short-
term pain treatment, e.g. after dental surgery. In addition, administration of drugs orally or 
sublingually has a lower risk of abuse than intravenous use. Genotyping was performed to 
exclude any poor metabolizers of methadone. Poor metabolizers are shown to have higher 
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concentrations of methadone in blood after intake and thereby have a higher risk of side 
effects or overdosing. 
Studies with opioids require a lot of resources as medically trained staff are necessary to 
assist the study. A medical doctor was present most of the time during the test days, and the 
testing facilities were close to the university hospital and ER. Treatment with opioid 
antagonist naloxone was available in case of symptoms of an overdose. All study assistants 
were instructed to look for signs of an opioid-overdose: lack of consciousness and/or 
respiratory depression. All female participants had to take a pregnancy test on the morning 
of every test day, before drug administration. 
About 100 studies have been conducted with the on-road driving test over the last 30 years 
at the Maastricht University (151). The driving instructors accompanying the participants are 
very experienced and there have never been any accidents. Still, the possibility that an 
incident could occur is always present. This could be serious and even fatal, both for the 
participants, the driving instructor and others present on the highway.  
Approval for the clinical study was obtained from the independent Ethics Committee of the 
Maastricht University and the Academic Hospital Maastricht in The Netherlands (Papers II 
and III: reference number NL57504.068.16 / METC163031) and the Regional Committees for 
Medical and Health Research Ethics in Norway (Papers II and III: reference number 2012/319 
C). The clinical study was conducted according to the code of ethics on human 
experimentation established by the Declaration of Helsinki (1964) and amended in 
Fortaleza, Brazil (2013) and in accordance with the Medical Research Involving Human 
Subjects Act. 
 
  
52 
 
  
53 
 
11. Results 
11.1. Paper I  
Can Patients Receiving Opioid Maintenance Therapy Safely Drive? A Systematic Review of 
Epidemiological and Experimental Studies on Driving Ability With a Focus on Concomitant 
Methadone or Buprenorphine Administration. 
Epidemiological studies performed in the 1970’s found that methadone-maintained patients 
(MMPs) did not have an increased crash risk compared to a control group. More recent 
studies did however find an increased risk of road traffic crash involvement in male patients 
treated with methadone and an increased odds ratio for being responsible for the crash in 
injured drivers exposed to either methadone or buprenorphine. It is difficult to draw firm 
conclusions with regards to crash risk among OMT patients based on the few studies 
performed.  
Previous experimental studies showed that single doses of methadone and buprenorphine 
to current opioid users or patients in OMT caused impairment in a minority of the tests, and 
buprenorphine even improved performance in a few tests. MMPs were impaired as 
compared to controls in approximately half of the tests, while the few studies comparing 
performance before and after long-term treatment showed both impairment and 
improvement from baseline measures. One third of the studies on buprenorphine 
maintained patients (BMPs) showed no difference in performance compared to controls. 
Furthermore, individuals in BMPs performed somewhat better than individuals in MMPs, but 
this could be attributed to reasons other than the treatment drug, like previous (drug) 
history and subject characteristics. 
Only a few studies on the performance of healthy volunteers after administration of single 
doses of methadone or buprenorphine have been performed. The studies reviewed found 
that both drugs have impairing potential in opioid-naïve subjects, and some dose-dependent 
effects were observed after both drugs. The results were somewhat difficult to interpret as 
none of the studies had included a benchmark substance.  
The review revealed that there was a complete lack of experimental studies on the effects of 
methadone and/or buprenorphine on actual on-road driving. In addition, there was a lack of 
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experimental studies using comparator drugs, using standardized tests, and studies 
measuring blood drug concentrations at the time of testing. 
11.2. Paper II 
A clinical trial on the acute effects of methadone and buprenorphine on actual driving and 
cognitive function of healthy volunteers. 
An on-road driving test was used to assess the acute effects of analgesic doses of 
methadone and buprenorphine on SDLP. Buprenorphine 0.4 mg mildly impaired driving 
measured by the SDLP. Neither the low dose of buprenorphine (0.2 mg) nor any of the doses 
of methadone (5 or 10 mg) had impairing effects on SDLP. Impairment was however 
apparent at the individual level as four participants stopped their driving tests during 
methadone or buprenorphine condition due to sleepiness.  
Seven computerized tests were used to evaluate neurocognitive function. In addition, 
questionnaires were used for subjective measurements like sleepiness, alertness and 
contentedness. Both opioids produced some cognitive and clinical impairments and 
increased sleepiness, and these effects were more pronounced after the high doses, see 
Table 1 and Table 3. 
Buprenorphine produced more significant effects compared to methadone. More significant 
effects were observed in the afternoon compared to the morning for both drugs. Side effects 
were often observed after both drugs; the most frequently reported side effects were 
nausea, vomiting, dizziness and tiredness/sleepiness. 
Drug concentrations in blood showed that the driving test was conducted around Tmax with 
regards to methadone, but after Tmax for buprenorphine.  
11.3. Paper III 
Pharmacokinetics of single doses of methadone and buprenorphine in blood and oral fluid, 
and correlation with effects on psychomotor and cognitive functions.  
Significant correlations were found between some neurocognitive effects, including SDLP, 
and buprenorphine concentrations in blood. Subjective measurements of sleepiness and 
alertness also showed a significant correlation. Most of the positive correlations were found 
in the morning, which coincides with the Tmax of buprenorphine, see Table 2 and Table 4.  
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Significant correlation between neurocognitive effects and methadone concentrations in 
blood were only found for DSST in the afternoon.  
Concentrations of methadone and buprenorphine in blood and oral fluid showed large inter-
individual variations, and accordingly also the oral fluid/blood concentration ratios. 
Buprenorphine concentrations in blood were in general very low and were no longer 
detected in blood 6.5 hours after drug administration. Only one third of the blood samples 
had buprenorphine concentrations above the LOQ, while nine of the subjects did not have 
concentrations of buprenorphine above the LOQ after the low dose of buprenorphine (0.2 
mg).  
 
11.4. Additional results 
11.4.1. Summary of results from the clinical study 
The results from the clinical study (reported in papers II and III) regarding dose- and 
concentration-related effects are summarized in Table 1, Table 2, Table 3 and Table 4. The 
results have been summarized to give an overview of the findings that were reported in two 
separate papers. 
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Table 1 Summary of results of the clinical study showing the significant effects as compared 
to placebo (indicated with *) as well as the significant dose-related effects between low and 
high doses (indicated with ‡) in the morning and afternoon condition. Bup = buprenorphine, 
Met = methadone. 
 Morning Afternoon 
Test Bup 
0.2 mg 
Bup 
0.4 mg 
Met 
5 mg 
Met 
10 mg 
Bup 
0.2 mg 
Bup 
0.4 mg 
Met 
5 mg 
Met 
10 mg 
SDLP - * - -     
PVT - * - - * */ ‡ - * 
CTT - * - - - */ ‡ - - 
DAT - */ ‡ - - * */ ‡ - */ ‡ 
DSST - */ ‡ - - - */ ‡ - */ ‡ 
DT/S1 - */ ‡ - */ ‡ - */ ‡ - * 
UFOV - - - - - * - * 
PBT - */ ‡ - - * */ ‡ ** * 
Tests 
showing 
impairment  
0 % 57 % 0 % 7 % 40 % 79 % 7 % 64 % 
 
Table 2 Summary of results of the clinical study showing significant correlations between 
drug concentrations in blood and impairment levels observed during on-road driving and 
neurocognitive performance (indicated with *) in the morning and afternoon 
 Morning Afternoon 
Test Buprenorphine Methadone Buprenorphine Methadone 
SDLP * -   
PVT * - - - 
CTT - - - - 
DAT * - * - 
DSST * - - * 
DT/S1 - - - - 
UFOV - - - - 
PBT * - - - 
Tests showing correlation  47 % 0 % 7 % 7 % 
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Table 3 Summary of results of the clinical study showing significant effects as compared to 
placebo (indicated with *) as well as significant dose-related effects between low and high 
doses (indicated with ‡) of the SCTI, the KSS and the Bond and Lader (B&L) in the morning 
and afternoon condition. Bup = buprenorphine, Met = methadone. 
 Morning Afternoon 
Test Bup 
0.2 
mg 
Bup 
0.4  
mg 
Met 
5  
mg 
Met 
10 mg 
Bup 
0.2  
mg 
Bup 
0.4  
Mg 
Met 
5  
mg 
Met 
10  
mg 
SCTI 
Walk-on-line 
 
- 
 
* 
 
- 
 
* 
    
Gait-on-line - - * *     
Finger-finger-test - */ ‡ - *     
Finger-nose-test - - - -     
Romberg’s test * * - *     
Overall impression * * - *     
KSS - */ ‡ - * * * ** * 
B&L Alertness - */ ‡ - * * * ** * 
Contentedness - * - - * * - - 
Calmness - - - - - ‡ - - 
Tests showing impairment 20 % 70 % 10 % 60 % 75 % 100 % 50 % 50 % 
 
 
Table 4 Summary of results of the clinical study showing significant concentration-related 
effects (indicated with *) of the SCTI, the KSS and the B&L in the morning and afternoon. 
 Morning Afternoon 
Test Buprenorphine Methadone Buprenorphine Methadone 
SCTI - -   
KSS * - - - 
B&L Alertness * - * - 
Contentedness * - - - 
Calmness - - - - 
Tests showing correlation 30 % 0 % 25 % 0 % 
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11.4.2. Concentrations of methadone and buprenorphine in blood 
The mean drug concentrations in blood are given with ranges to demonstrate the large 
inter-individual differences observed in our data, see Table 5, Figure 21 and Figure 22. 
 
Table 5 Mean concentrations (range) of methadone and buprenorphine in whole blood 
(ng/mL). 
 
Time after 
drug 
administration 
(hours) 
 
Buprenorphine 
0.2 mg 
(ng/mL) 
 
n 
 
Buprenorphine 
0.4 mg 
(ng/mL) 
 
n 
 
Methadone 
5 mg 
(ng/mL) 
 
n 
 
Methadone 
10 mg 
(ng/mL) 
 
n 
 
1 
0.07  
(0.02-0.17) 
 
20 
0.14  
(0.02-0.30) 
 
21 
4.5  
(0.0-14) 
 
19 
5.9  
(0.0-19) 
 
20 
 
2 
0.10  
(0.04-0.18) 
 
21 
0.18  
(0.00-0.33) 
 
21 
9.3  
(1.0-14) 
 
20 
17  
(6.0-35) 
 
20 
 
3.5 
0.07  
(0.01-0.16) 
 
22 
0.13  
(0.04-0.22) 
 
21 
11  
(6.0-18) 
 
20 
20  
(12-30) 
 
20 
 
6.5 
0.02  
(0.00-0.08) 
 
21 
0.04  
(0.00-0.09) 
 
20 
8.0  
(3.4-12) 
 
19 
16  
(10-22) 
 
20 
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Figure 21 Mean concentrations of methadone in blood after 5 and 10 mg, including range for 
methadone 10 mg. The associated concentrations in blood at the time of the neurocognitive 
tests were measured 2 and 6.5 hours after drug administration in the morning and 
afternoon, respectively, while the concentrations measured at 3.5 hours were associated 
with the driving test including SDLP. 
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Figure 22 Mean concentrations of buprenorphine in blood after 0.2 and 0.4 mg, including 
range for buprenorphine 0.4 mg. Indicated in the figure is also the LOQ of 0.09 ng/mL. The 
associated buprenorphine concentrations in blood at the time of the neurocognitive tests 
were measured 2 and 6.5 hours after drug administration for the morning and afternoon, 
respectively, while the concentrations measured at 3.5 hours were associated with the 
driving test including SDLP. 
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11.4.3. Predisposing factors for impairment 
I chose to look at two possible factors, i.e. body mass index (BMI) and sex, which could 
possibly influence concentrations in blood and the degree of impairment. Bivariate 
correlations were used to evaluate associations between opioid concentrations in blood and 
sex and BMI, respectively. A significant correlation was found between blood methadone 
concentrations and sex; analysis showed that females had a higher mean concentration level 
than men (r=.263, p=0.019). No significant correlation was found between drug 
concentrations in blood and BMI. Figure 23 show mean methadone concentrations in blood 
for males, females, BMI <24.4 and BMI>24.4, respectively. Since all mean buprenorphine 
concentrations in blood were below the LOQ no conclusions could be drawn for 
buprenorphine. 
 
 
Figure 23 Mean concentrations of methadone in blood for male and females at different 
BMIs. A significant correlation between concentration of methadone in blood and sex was 
found. 
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11.4.4. Effect sizes 
Effect sizes (ES) were calculated to determine the magnitude of the effects of the different 
treatment conditions, using Dunlap’s effect size for repeated measures (i.e., tc[2(1−r)/n]1/2) 
(152) for the DAT, PBT and PVT, see Table 6. Paired samples t-test was calculated for each 
treatment condition, and the t-value (tc), correlation (r) and number of subjects (n) were 
determined. ES between 0 and 0.2 are considered small, between 0.2 and 0.7 are considered 
moderate and 0.7 or higher are considered large (153). The ES were compared with the ES of 
three different levels of BACs (i.e. 0.02, 0.05 and 0.08 %) that have been investigated in a 
previous study (92). DAT, PBT and PVT were chosen because they have been shown to be 
the most sensitive tests to detect impairing effects of alcohol and also to determine the 
magnitude of the effects of alcohol (14, 92).  
Table 6 shows that for DAT the low doses of buprenorphine and methadone exceeded the ES 
of BAC 0.05 %, while the ES for the high dose of buprenorphine exceeded the ES of BAC 0.08 
%, all treatment conditions were in the afternoon session 6 hours after drug administration. 
In the “PBT – eyes open” no treatment condition exceeded the ES of BAC 0.05 %, while the 
high doses of both drugs exceeded the ES of BAC 0.05 % in the “PBT – eyes closed” 
afternoon condition. Finally, the ES of PVT after all treatment conditions in both the morning 
and the afternoon, except methadone 5 mg in the morning, exceeded the BAC of 0.05 %, 
and the ES of 10 mg methadone (afternoon) even exceeded the ES of BAC 0.08 %. 
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Table 6 Effect sizes (Dunlap’s) of the performance tests DAT, PBT and PVT. The results for 
three different BAC levels have been published in a previous study and serve as a benchmark 
substance for our results (92).  
Bup = buprenorphine; Met = methadone; PLA = placebo 
 
 Time of 
testing 
(h) 
PLA  
vs  
Bup 
0.2  
mg 
PLA  
vs  
Bup 
0.4  
mg 
PLA  
vs  
Met 
5  
mg 
PLA  
vs  
Met 
10  
mg 
PLA  
vs  
BAC 
0.02 % 
PLA  
vs  
BAC 
0.05 % 
PLA  
vs  
BAC 
0.08 % 
DAT 
Reaction time (ms) 
     0.34 0.39 0.65 
  +2 0.02 0.37 0.06 0.37    
  +6 0.59 0.82 0.41 0.37    
PBT - Eyes open       0.39 0.77 1.5 
 +2 0.02 0.48 -0.10 0.25    
 +6 0.39 0.52 0.31 0.71    
PBT - Eyes closed       0.22 0.62 0.96 
 +2 0.08 0.45 0.18 0.09    
 +6 0.46 0.82 0.38 0.73    
PVT 
Reaction time (ms) 
     0.16 0.31 0.68 
 +2 0.34 0.37 -0.06 0.37    
 +6 0.60 0.63 0.44 0.73    
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12. Discussion 
12.1. Appraisal of the main findings 
12.1.1.  The current knowledge regarding crash risk and impairing effects on 
driving after administration of methadone and buprenorphine 
12.1.1.1. Epidemiological studies on crash risk 
The review published in Paper I included five epidemiological studies of traffic risk after 
exposure to methadone or buprenorphine. The first epidemiological studies on traffic risk 
were conducted from 1973 to 1977 (154-156). All of these studies showed that there was no 
difference in accident involvement and seriousness of convictions between methadone-
maintained patients and drivers in the control groups. The next epidemiological study was 
published in 2010 (157), more than 30 years later. The study showed an increased odds ratio 
for culpability but no association between exposure to methadone and buprenorphine and 
road traffic crash. Other studies on chronic use of opioids and traffic risk that have been 
published in recent years support an increased risk of crash culpability in users of 
methadone and buprenorphine (26) and an increased risk of traffic accident involvement in 
male methadone users (24). 
It is interesting that there is a long time gap between the published epidemiological studies. 
Methadone-maintained patients and patients with chronic opioid use have been driving 
during the whole period and traffic crash risk has been studied for several other drugs during 
this period. One possible explanation for this lack of studies might be that it was not 
considered necessary to follow up three different studies that all showed no increase in 
accident involvement among methadone-maintained patients. Another reason could be that 
driving during OMT and chronic opioid use was considered a marginal problem. The different 
results between the studies from the 1970’s and the more recent studies could however be 
attributed to methodological differences as discussed in chapter 12.2.1. 
12.1.1.2. Experimental studies on impairing effects of drugs 
Our review included 54 experimental studies on performance of OMT patients and opioid-
naïve subjects after single doses of methadone or buprenorphine. It was not possible to 
perform a meta-analysis due to the low number of studies included. 
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The results showed that methadone and buprenorphine caused some degree of impairment 
in opioid-tolerant subjects in OMT. This indicates that treatment with both drugs can harm 
safe driving. On the other hand, impairment was only revealed in a small fraction of the 
tests, and in some studies improved performance of tests was found. This could indicate that 
the majority of patients in OMT are fit to drive. It is, however, worth noting that the 
improvement of neurocognitive performance observed in some OMT patients are not 
necessarily due to drug effects, but could be attributed to other reasons, e.g. a general 
improvement of performance following stabilization after treatment and follow-up. It can be 
difficult to determine the level of impairment acceptable in road traffic for OMT patients 
compared to other patient groups, or even normal variation in the general driving 
population. The studies do not provide evidence that there are subgroups with specific 
characteristics that are more or less fit to drive; i.e. there were no differences between 
groups when they were classified in long-term versus short-term treatment or high versus 
low daily dosage.  Based on the current knowledge, where considerable individual 
differences were observed in experiential studies, an individual assessment of fitness to 
drive is considered to be the best approach to patients in OMT with regards to the ability to 
drive. 
We found that no experimental studies had been performed to study the acute effects of 
single doses of methadone and buprenorphine on actual on-road driving in healthy 
volunteers. Furthermore, the previously performed studies had several shortcomings: 
there was no use of a benchmark substance; few pharmacokinetic measurements were 
performed; and the tests were not standardized to reveal driving related impairment.  
Only eight studies were performed after administration of single doses of methadone and 
buprenorphine to healthy volunteers. One of the studies was published in 2008, the 
remaining studies were from 1997 or older. Similar to the epidemiological studies, the 
reason for this time gap is probably that the topic was considered a minor problem. 
Presumably there is a small group of opioid-naïve persons that get opioids prescribed. 
Driving related impairment is therefore only relevant to very few persons, either when 
initiating treatment with opioids or during short-term treatment. In the case of short-term 
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treatment, e.g. after oral surgery, it is recommended to abstain from driving during the few 
days of treatment.  
Methadone and buprenorphine are not first choice analgesics to opioid-naïve patients, and 
the question of fitness to drive in relation to such treatment is thus not frequent. Even so, 
few studies have been conducted to investigate whether these drugs induce traffic 
impairment, and both drugs are frequently seen in drivers suspected for driving under the 
influence of drugs. In tolerant subjects the question of impairment will highly rely on the 
degree of tolerance. Several studies suggest that there are few impairing effects of opioids in 
opioid-dependent or tolerant patients (88, 158).  
12.1.2. Do methadone and buprenorphine cause traffic relevant impairment and is 
there a dose- and/or concentration-effect relationship for methadone and 
buprenorphine? 
Previous experimental studies have shown that methadone and buprenorphine have acute 
impairing effects on driving related skills, and our results from the clinical study are in line 
with this. An evidence table with a summary of the results from the experimental studies 
included in the review is shown in Paper I (Table 5). Previous studies have shown a 
significant decrease in performance of the DSST after buprenorphine administration (134, 
159, 160). We found dose-dependent effects and concentration-effect relationship for the 
DSST after administration of both methadone and buprenorphine. Buprenorphine has been 
shown to impair tests of reaction time, while methadone has been shown to induce dose-
related impairment of reaction time. We found that buprenorphine alone impaired reaction 
time (PVT and DAT) in both a dose-dependent and a concentration-related manner. We also 
confirmed that buprenorphine caused significant impairment on tests of attention.  
12.1.2.1. Methadone  
No effect was seen on the SDLP after methadone 5 and 10 mg, and no correlation between 
drug concentration in blood and effect was found for the driving test. We did observe some 
effects on the neurocognitive tests, especially at the higher dose, indicating that methadone 
has impairing effects on some parts of driving-relevant behavior. However, no correlation 
was found between methadone concentration in blood and effects on the neurocognitive 
tests. 
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Table 1 shows that methadone 10 mg impaired 64 % of the tests including subtests in the 
afternoon but only 7 % in the morning. With regards to the clinical relevance of the results, it 
seems like the high dose of methadone causes impairment in most tests performed and 
even caused effect sizes exceeding those following a BAC of 0.05% in a few tests, see Table 
6.  The question remains whether the impairing effects of methadone would have been 
more pronounced if higher doses were administered. 
The impairing effects of the high dose of methadone on neurocognitive tests were not 
observed in significant changes in SDLP during on-road driving. However, two driving tests 
were prematurely terminated after administration of the high dose of methadone, indicating 
a notable individual variation in impairment levels.  
12.1.2.2. Buprenorphine  
Buprenorphine 0.4 mg was the only treatment condition that caused significant impairment 
of the SDLP as compared to placebo. The mean SDLP increase did not exceed the +2.5 cm 
threshold for impairment comparable to a BAC of 0.05 % (i.e. clinical relevance criterion), 
but the CI of the mean change in SDLP (+2.49 cm) almost included the +2.5 cm threshold. 
However, a correlation was found between concentration of buprenorphine in blood and 
change in SDLP. The results show that there is a concentration-dependent effect of 
buprenorphine on the SDLP of the driving test, at least in lower concentration levels such as 
those measured in our study. Furthermore, the driving test was prematurely terminated on 
two occasions after administration of the high dose and one occasion after the low dose, 
indicating significant individual variation in impairment levels.  
Buprenorphine 0.4 mg significantly impaired the driving test. Furthermore, impairment was 
observed after the same dose in 57 % and 79 % of the neurocognitive tests including 
subtests in the morning and afternoon, respectively. Concentration-effect correlation was 
observed in 47 % of the tests in the morning, around Tmax.  
Buprenorphine additionally impaired most of the neurocognitive tests performed. The tests 
include all three levels of behavior recommended for research to assess driving related drug-
impairment. Dose-dependent impairment was observed for most tests when performed in 
the afternoon, and for some in the morning, see Table 1. Concentration-effect correlations 
were seen in most of the tests when measured in the afternoon, see Table 2.  
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With regards to the clinical relevance of the results from the neurocognitive tests, it can be 
stated that both the number of tests showing impairment as well as the effect size 
calculated (for three of the tests) shows that buprenorphine causes impairment of skills 
related to driving. The effect sizes were comparable to a BAC of 0.05% for at least some of 
the tests. It could, however, have been useful to calculate the effect size for all tests 
performed in our study. In conclusion, it seems that even low doses of buprenorphine are 
potent when administered to opioid-naïve subjects, and that buprenorphine has impairing 
effects of relevance to driving skills.  
12.1.2.3. More pronounced effects in the afternoon condition 
The effects on the neurocognitive tests and the subjective measures were more pronounced 
in the afternoon as compared to the morning, see Table 1 and Table 3. We observed that 
Tmax for buprenorphine occurred around 2 hours after drug administration, while Tmax for 
methadone was seen after around 3.5 hours. Consequently, all of the tests measured in the 
afternoon were performed at decreasing drug concentrations in blood, i.e. after the Cmax. 
There could be several possible explanations for the observed delay in effect as compared to 
the Cmax: increasing sleepiness during the test day; hysteresis due to time to drug crossing 
the blood-brain barrier or time to receptor-binding; or effects of active metabolites. 
Buprenorphine 0.4 mg impaired the driving test and all of the neurocognitive tests in the 
afternoon, see Table 1.Cmax was observed 2 hours after drug administration. At the time of 
the testing in the afternoon, the drug concentrations of buprenorphine were below the LOQ, 
i.e. more pronounced effects were found with descending concentrations.  
The increasing percentage of significant effects on neurocognitive tests and subjective 
measures for both methadone and buprenorphine were not associated with higher drug 
concentrations in blood. All treatment conditions caused sleepiness and reduced alertness in 
the afternoon. This could explain the more pronounced effects on neurocognitive tests in 
the afternoon.   
An alternative explanation to the delay in effect as compared with the drug concentrations 
in blood can be explained by a hysteresis plot, see Figure 24. Hysteresis in drug response 
means that there is a time delay between the measured drug concentration and the effect 
response. Buprenorphine hysteresis has previously been described (161, 162). Our findings 
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suggest a counter-clockwise hysteresis loop for buprenorphine. The most common reasons 
for counter-clockwise hysteresis lagging is limited access to the receptor site or slow 
receptor kinetics (163). 
 
 
Figure 24 Counter-clockwise hysteresis loop illustrating the lagged drug effect compared 
with the drug concentrations. 
 
The lag of effects was most pronounced for buprenorphine. Possible explanations to the 
delayed buprenorphine effects are delay in transport across the blood-brain barrier, efflux of 
drug across the blood-brain barrier or time to receptor-binding in the CNS.  
For morphine a delay in effect has also been described (72), and it was suggested that the 
delay was due to the metabolism to an active metabolite (morphine-6-glucuronide) which 
itself contributed to the effects. This does not seem to be the case for methadone as it has 
no active metabolites. Buprenorphine is, however, metabolized to norbuprenorphine, which 
is biologically active. The effects of norbuprenorphine have mainly been studied in vitro 
(164) and in animals (165), and are inconclusive.  
12.1.2.4. The simplified clinical test of impairment (SCTI) 
The SCTI was performed 2 hours after drug administration, see Table 3 and Table 4. The low 
doses of both drugs caused little impairment on the subtests. As both the gait-on-line and 
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Romberg’s test are tests of balance, it could be suggested that both doses of methadone and 
buprenorphine impair balance. The postural balance test (PBT) was performed both 2 hours 
and 6 hours post drug-intake. After 2 hours the high dose of buprenorphine impaired the 
PBT. In the eyes closed condition after 6 hours all treatments impaired the PBT. This also 
indicates that balance is sensitive to the effects of the opioids tested.  
Many of the volunteers seemed unaffected, as observed by the research assistants, and felt 
fine until the SCTI was performed. Especially the gait-on-line revealed that they were indeed 
impaired at the time of testing. These results show that balance might be affected by 
opioids, and that poor balance as revealed by a clinical test could, among other causes, 
indicate opioid use. The finding might also indicate that caution may be required in persons 
with pre-existing balance problems, especially elderly, when initiating or adjusting opioid 
treatment.  
Previous studies on opioids and CTI have found that impairment did correlate with morphine 
concentration in blood after heroin intake (166), while this was not the case after codeine 
intake (167). We found no correlation between concentration of methadone in blood and 
overall impression of the clinical test of impairment, see Table 4. This is also shown in a 
previous study (n=10) (41). Yet, the high dose of both buprenorphine and methadone did 
affect most of the subtests of the SCTI, see Table 3. 
12.1.3. The pharmacokinetic properties of methadone and buprenorphine in blood 
and oral fluid 
12.1.3.1. Concentrations of buprenorphine and methadone in blood 
Mean drug concentrations in blood including range are shown in Table 5,Figure 21 and 
Figure 22. The ranges were especially large after the high doses of methadone and 
buprenorphine. E.g. the mean concentration in blood 2 hours after administration of 0.4 mg 
buprenorphine was 0.38 nM, with a range from 0.00 to 0.70 nM.  
Only 36 % of the buprenorphine concentrations in blood were above the LOQ. After the low 
dose (0.2 mg) 27 % of the blood samples had concentrations above LOQ, while 61 % were 
above the LOQ after the high dose (0.4 mg). This shows that our samples were in a very low 
concentration-range for buprenorphine. When extrapolating drug concentrations to levels 
expected after administration of lower doses, our concentrations of buprenorphine were 
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below what would have been expected from previously reported studies. Yet, low 
concentrations of buprenorphine have previously also been a challenge when studying the 
pharmacokinetics of buprenorphine (125). The reason is that buprenorphine is very potent; 
therefore, acute doses and accompanying concentrations in blood are very low.   
Since a large proportion of the buprenorphine concentrations were below the LOQ, these 
concentrations cannot be accurately measured, and the concentrations cannot be used to 
calculate ratios. Still, concentrations below a certain limit, in this case the LOQ, could be 
used to evaluate effects as compared to higher concentrations, i.e. calculate correlations. 
The small variations in accuracy in the lowest range of concentrations are presumably of 
little importance when comparing low and high concentrations. However, this might 
constitute a problem if there is a small range in concentrations, i.e. small deviations can 
cause significant results. In our study both doses of buprenorphine showed large ranges in 
concentrations in blood, and for this reason we chose to calculate correlations between 
concentration and effect for buprenorphine. 
Poor metabolizers of CYP2B6 were excluded from the study. Thus, the large variation in 
methadone concentration in blood is not due to variation in CYP2B6 metabolism. Variations 
in drug concentrations in blood due to metabolism via other CYP-enzymes can, however, not 
be excluded.  
12.1.3.2. Concentrations of methadone and buprenorphine in oral fluid 
Our results show that reliable concentrations of methadone or buprenorphine in blood 
cannot be calculated based on concentrations in oral fluid due to large individual variations. 
Reliable oral fluid/blood ratios have also not been established in previous studies. Oral fluid 
sampling will therefore not be a useful tool with regards to evaluating degree of impairment 
in drug drivers. 
12.1.3.3. Predisposing factors for impairment 
Large inter-individual variations were observed in both the effect (pharmacodynamics) as 
well as concentrations in blood (pharmacokinetics). This raised the question whether there 
are any objective predisposing factors to determine which subjects could expect to have 
more effects and higher concentrations in blood. Variation in effects of opioids is known 
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from pain treatment, e.g. non-responders to pain treatment with morphine (168). It is not 
known if response to pain treatment could also be translated into driving impairment.  
While performing the clinical study observations of the subjects were made with regards to 
effects and side effects, which raised questions whether sex and/or weight (i.e. body mass 
index or BMI) influenced the degree of impairment. A significant correlation was found 
between methadone concentrations in blood and sex, with females having significantly 
higher mean concentrations than males, see Figure 23. Even though women had higher 
concentration levels of methadone, the SDLP mean values did not differ significantly 
between the sexes. Some sex differences were found when performing bivariate correlation 
analysis, but most of the differences were found for the same tests (DAT, CTT and PVT) in all 
treatment conditions including placebo. Men were significantly more sleepy after 
buprenorphine administration than women, as measured with the KSS. After administration 
of methadone, women were less alert than men as measured with the Bond & Lader.  
All mean buprenorphine concentrations in blood were below the LOQ. For this reason no 
comparison between groups could be made for buprenorphine. 
Factors other than sex and BMI seem pivotal to identify persons who are more sensitive to 
the effects of opioids. Other possible factors that could determine the pharmacodynamics of 
methadone and buprenorphine are opioid receptors and opioid receptor genes (98) and 
transport across the blood-brain barrier (97). 
12.1.3.4. Inter-individual variations in pharmacokinetics and 
pharmacodynamics 
Few effects were found on group level but large individual variations were seen. An example 
from our clinical study is a male subject who in the buprenorphine 0.4 mg condition was 
clearly sedated before conducting the driving test. During the oral fluid sampling, ten 
minutes before the driving, he almost fell off the chair he was sitting on. He felt able to carry 
out the driving though, and he did complete half of the test. But after driving approximately 
30 minutes he fell asleep while taking the exit from the highway to make the turnaround. He 
had the highest SDLP measured in the entire study. He was clinically clearly impaired and 
sedated. Still, he actually drove for 30 minutes. The change in SDLP (∆SDLP) for this subject 
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was 8.38 cm compared to the placebo condition, while the mean ∆SDLP for the group in the 
0.4 mg buprenorphine condition was 1.12 cm.  
On the other hand, 6 of the 22 participants (27 %) performed better in the buprenorphine 
0.4 mg condition as compared to the placebo condition. Large variations were also observed 
for drug concentrations in blood. It is worth noting that the three subjects with the highest 
∆SDLP were also the only ones with drug concentrations above the LOQ. There was a 
positive correlation between drug concentration in blood and change in SDLP after 
buprenorphine 0.4 mg, as described in Paper III. 
Large individual variations were also observed for methadone: the mean ∆SDLP was 0.17 cm 
(range from -2.54 to 2.97 cm) after 5 mg methadone and 0.42 cm (range from -4.51 cm to 
4.46 cm) after 10 mg methadone. But neither doses of methadone caused significant 
impairment of the SDLP compared to placebo. Additionally, four subjects decided to 
terminate the driving test on six occasions due to sleepiness, in both the methadone and the 
buprenorphine condition. The question remains whether there are individual factors that 
would help us to predict which subjects will be more impaired than others when using these 
drugs, as discussed in chapter 12.1.3.3. 
12.2. Methodological discussion  
12.2.1. Epidemiological studies in the literature review 
The epidemiological studies performed in the 1970’s have one common major limitation: all 
three studies were based on self-reporting, which could lead to information bias. 
Information regarding substance exposure as well as concomitant use of psychoactive drugs 
other than methadone and buprenorphine might be inaccurate; underreporting is common. 
Furthermore, self-reported information regarding driving violations and accidents might be 
inaccurate.  
The methods used were different in the studies conducted in the 1970’s and after 2010: the 
1970’s studies used mainly questionnaires while more recent studies use 
incidence/prevalence data to calculate the risk. The results could indicate a difference in the 
sensitivity of the methods used. 
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Only five epidemiological studies on crash risk after exposure to methadone were included 
in the review, and the number of subjects included were relatively low, ranging from n=26 
(24) to n=781 (154). The low numbers of studies and subjects make it difficult to draw firm 
conclusions regarding crash risk in this group.  
12.2.2. Experimental studies in the literature review 
There were several methodological limitations in the papers which have been included in 
paper I: the doses administered varied considerably between the studies; few studies 
measured drug concentrations in blood; few studies included alcohol as a benchmark 
substance; past and present drug use was unknown; and the tests used were not 
standardized. These shortcomings constitute a significant problem when evaluating the 
results from the papers.  
The dosages administered varied between the studies, but there did not seem to be any 
difference in test results between those who received low and high doses of the drugs. It 
would be interesting, though, if a separate study was designed to distinguish between low 
and high doses.  
No drug concentrations in blood were measured, and it would have been interesting to 
know the variation in concentrations among the patients. Furthermore, it would also have 
been interesting if correlation between drug concentrations in blood and effects were 
calculated. 
Lack of a benchmark substance is a considerable shortcoming and is important to show 
sensitivity to drug-induced impairment in the participants and to calibrate to other studies. 
Past and present drug use is crucial information when evaluating the results in experimental 
studies. It is important to control for concurrent use of opioids and psychoactive drugs as 
this could confound the results. A study on MMPs showed that the subjects testing 
positive for other psychoactive drugs performed markedly worse than those testing 
negative (169). Drugs other than the drug in question might significantly impair the tests 
performed, as can drug-interactions. Furthermore, current opioid abusers show more 
impairment than matched controls (170). Previous abuse/dependence of psychoactive 
substances could also influence the test results on neurocognitive performance 
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depending on the type of drug used, e.g. long-term abuse of opioids is associated with 
cognitive deficits which may contribute to cognitive impairment (171). On the other hand, 
tolerance is known to develop to effects of opioids and should also be taken into 
consideration when impairment is evaluated.   
Another shortcoming is the great diversity in tests applied, which makes comparison 
between studies difficult.  
Finally, in studies with OMT patients the subjects are not randomized. Furthermore, the 
factors determining the selection to treatment groups, i.e. either methadone or 
buprenorphine treatment, could be the explanation to all differences observed between 
the groups (i.e. confounding by indication). This could explain why BMPs performed 
somewhat better than MMPs.  
12.2.3. Selection of tests used in the clinical study 
As opioids have CNS depressant effects, we chose tests for assessing impairment caused by 
sedation. A review of the literature has shown that a number of tests are preferably used to 
study such impairment. Experimental studies assessing effects of sedation on driving and 
driving related skills in healthy volunteers concluded that several performance measures 
were sensitive to the impairing effects of sedation. SDLP, the primary performance measure 
in the on-the-road driving test, has been found to be sensitive to the impairing effects of 
antidepressants (172), antihistamines (173), and residual effects of hypnotics (142, 174, 
175). 
The on-road driving test has become a gold standard for measuring drug effects on driving 
(151). Obvious advantages are the realistic driving setting with control of lateral position and 
speed, adaption to traffic and a long duration of the test. Disadvantages include the inability 
to assess risk assessments and behavior at unforeseen incidents, e.g. distractions caused by 
pedestrians or traffic light, and that driving-complex skills are not tested. The primary 
outcome of the on-road driving test is the SDLP, which measures road tracking and sustained 
attention. The SDLP has been shown to differ considerably between subjects. 
Psychomotor vigilance (176), psychomotor performance (177) and postural control (178) 
are sensitive domains to measure sleepiness-induced impairment. Moreover, divided 
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attention was found to be sensitive to the impairing effects of antidepressants (172, 179), 
antihistamines (173), and residual effects of hypnotics (142, 175). Studies conducted with 
the Vienna Test System (180) showed that the Determination Test is sensitive to drug-
induced changes (181, 182). In a previous study of laboratory tests, it was found that the 
PVT, DAT and the postural balance test were sensitive to the impairing effects of alcohol 
in a dose-dependent manner (14). The DAT, PVT and PBT are especially sensitive to the 
effects of alcohol, and effect sizes of three levels of BACs (0.02, 0.05 and 0.08 %) have been 
determined (92). 
The SCTI is a selection of the subtests used in the CTI and comprises mainly tests of balance. 
Other subtests, e.g. tests of memory, could possibly have affected the SCTI outcome 
differently. 
If the study was designed today, it would have been interesting to implement a subjective 
questionnaire for the volunteers to evaluate their fitness to drive. It would have improved 
the study to know if, in a naturalistic setting, the subjects would have driven, i.e. how they 
assessed their own degree of impairment before the driving test; and also, how they felt that 
the driving test went. This could have provided useful information with regards to patient 
information on potential driving impairment. If the subjects were aware of the impairing 
effects, like sleepiness, to such an extent that they would choose not to drive, this could 
have been translated to the patient’s situation. 
12.2.4. Sensitivity of the tests used in the clinical study 
It has been suggested that tests other than those sensitive to alcohol might be sensitive to 
opioids (28). Alcohol is by far the most studied drug which induces driving impairment and it 
is frequently used as a benchmark substance (14). The standardized on-road driving test has 
been applied in almost 100 studies and this allowed us to compare the effects on SDLP in the 
present study with those of alcohol and other drugs from previous studies.  
A meta-analysis of the effects of alcohol on driving related skills, performed as part of the 
DRUID project, found that psychomotor functions, such as reaction time, tracking and 
driving, were more impaired by alcohol (at a BAC of 0.04–0.059%) than cognitive functions 
like attention, visual functions and en-/decoding (183). The study combined the results from 
450 studies with a total of 5,300 findings of alcohol effects on performance. 
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A recent review suggests that morphine and possibly other opioids may cause effects on 
traffic-relevant performance tasks different from those shown to be sensitive to the effects 
of alcohol (72). The review found that attention and visual functions were the most sensitive 
to detect impairment after morphine intake, while psychomotor skills and en-/decoding 
were the least sensitive.  
However, this coincides with the findings from a recent review on the sensitivity of tests 
assessing driving related skills at medium (0.031–0.06%) to high (0.061–0.10%) BACs where 
it was stated that the DAT and the PVT are the most sensitive to the impairing effects of 
alcohol (92). Moreover, any effect due to buprenorphine or methadone on any psychomotor 
or cognitive test could potentially be of some importance to traffic safety. 
12.2.5. Lack of benchmark substance in the clinical study  
Lack of a benchmark substance is a considerable shortcoming in several experimental 
studies. The use of a benchmark substance could be important for several reasons: to show 
sensitivity to drug-induced impairment in the participants, to confirm sensitivity of the 
driving test and to calibrate to other studies (77).  
We chose not to include alcohol in our clinical study as this drug is already well studied in 
previous studies at the Maastricht University, using the same on-road driving test and 
neurocognitive tests, for references see (81). It was considered acceptable to use historical 
data to interpret our results. Furthermore, the burden for the participants would have been 
heavier if one more test day was added to the five test days. The study was already a 
considerable load consisting of five test days separated by a minimum of 10 washout days 
and including a training session and medical examination on two additional occasions.  
Yet, the use of a benchmark substance would have improved the study and strengthened 
the results. A benchmark substance known to impair SDLP, and where the magnitude of the 
impairment is known, like alcohol, would have been a useful positive control in our study.  
12.2.6. Time of testing in the clinical study 
Ideally the testing of the effects of the administered drugs should be around the time of 
Cmax, i.e. at Tmax. This is however challenging when two different drugs with non-identical 
Tmax are tested. Methadone reaches peak plasma concentrations at 2.5–4 hours after per 
oral intake, while buprenorphine plasma concentrations peak at 0.8–1.3 hours after 
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sublingual intake. To maintain a double-blind design, it was not possible to perform the 
driving test at different times for each treatment. The driving test was performed in the 
middle of the test day to allow the neurocognitive tests to be performed twice per test day.  
12.2.7. The chosen doses in the clinical study 
The doses administered were chosen based on doses previously given to healthy, opioid-
naïve volunteers and equianalgesic doses of morphine.  
The possibility that the doses of methadone (5 and 10 mg) could be too low to show 
significant differences in effects as compared to placebo was discussed during the planning 
of the study. We did discuss to administer 10 and 15 mg of methadone instead, but 
methadone 15 mg has never, to our knowledge, previously been administered to opioid-
naïve subjects. Methadone is a potent drug with risk of serious side effects such as 
respiratory depression, and 10 mg was chosen as the highest dose.  
Frequent and unpleasant side effects were challenging during the data collection in our 
study and caused many missing data. The number of side effects would have increased with 
higher doses, and further the risk that the subjects would not be able to complete all the 
psychomotor and cognitive tests.  
12.2.8. Predictive validity of the tests used in the clinical study 
It has been argued that the SDLP is only representative for parts of the tasks required for 
driving (i.e. tracking and sustained attention) and does not measure the more complex tasks 
related to driving. Yet, a high correlation (r = 0.99) has been established between SDLP 
increment following alcohol intake and the indirect risk of traffic crash involvement (89).  
The neurocognitive tests chosen in our study included all three behavioral levels (automative 
behavior, control behavior, and executive planning behavior) recommended for research on 
driving performance. It has been found that the DAT and the PVT, and also the PBT, were 
sensitive to alcohol effects and thereby are considered valid in assessing potential driving 
impairment (92). 
12.2.9. Measuring drug concentrations in blood in the clinical study 
Performing an on-road driving study including blood sampling is crucial if the results are to 
be used to set cut-off limits for impaired driving. It would have been interesting to collect 
more blood samples during the test days that would have provided more accurate 
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pharmacokinetic data, but this was not possible due to the very tight schedule on the test 
days.  
The buprenorphine concentrations in blood were very low, as described previously. The 
methods used to analyze the blood samples are sensitive. Still, we have seen that lower LOD 
and LOQ are required for measuring buprenorphine in blood when such low doses of 
buprenorphine are administered.  
The reliability of the laboratory tests was very good as all analysis were performed in an 
accredited forensic toxicological laboratory with validated methods. 
12.2.10. External and internal validity in the clinical study 
A good external validity of a study means that the results can be applied to a general 
population. In our clinical study the participants were not randomly chosen and a similar 
study in another study population might not provide the same results. The participants were 
healthy volunteers and do not represent pain patients. Furthermore, patients with chronic 
opioid use will develop tolerance to at least some of the effects of opioids. However, the 
study population is representative for persons who use opioids sporadically either as pain 
medication or recreationally.  
Internal validity describes how well an experiment is done and how well it can rule out 
alternative explanations (confounders) to the findings. We performed a randomized clinical 
trial, which is considered the “gold standard” of experimental research. Our participants 
were selected by several criteria, including good health and significant driving experience. 
This could cause a selection bias. The frequent side effects, and consequently many missing 
data, could have biased the results as poor performance was not included in the data 
analysis, thereby underestimating the impairing effects of the drugs.  
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13. Conclusions  
 
The literature review revealed that recent epidemiological studies have found an increased 
risk of road traffic crash involvement in male patients treated with methadone and an 
increased odds ratio for being responsible for the crash in injured drivers exposed to either 
methadone or buprenorphine. However, the studies included few cases, so firm conclusions 
should not be drawn. 
Furthermore, the literature review found that previous experimental studies on OMT 
patients showed impairment in some subjects, but also some improvement. However, 
methodological shortcomings make it difficult to compare the results between the different 
studies and draw conclusions. Patients treated with buprenorphine performed to a 
moderate extent better than methadone treated patients but the explanation for this might 
be reasons other than drug effects. 
Finally, the literature review showed that previous experimental studies revealed at least 
some traffic relevant impairment in drug-naïve subjects after single doses of methadone and 
buprenorphine. However, few such studies have been conducted and none on actual on-
road driving.  
Our clinical study is the first study where methadone and buprenorphine have been 
administered to opioid-naïve subjects and an actual on-road driving test was performed in 
addition to several neurocognitive tests, and where blood samples were collected 
throughout the test day for analysis of drug concentrations. Our study showed that 
buprenorphine 0.4 mg significantly impaired SDLP in the driving test, whereas equianalgesic 
doses of methadone did not. Even though mild effects on driving and driving related skills 
were observed it is worth noting that large individual variations were measured: Four out of 
22 subjects prematurely terminated the driving test due to sleepiness after both drugs. The 
impairing effects of methadone and buprenorphine on driving relevant tasks found in the 
clinical study are in line with previous studies that indicate that both methadone and 
buprenorphine have an impairing potential in opioid-naïve subjects. 
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Furthermore, we found dose-dependent effects on neurocognitive tests relevant to driving 
after administration of methadone and buprenorphine. However, few drug concentration-
effect correlations were found: some for buprenorphine but not for methadone. 
Buprenorphine significantly impaired the SDLP of the driving test, however, the effects did 
not reach clinical relevance, i.e. effects comparable to a BAC of 0.05 %. Reaching clinical 
relevance would imply that the relative risk of causing a road traffic crash is significantly 
increased. On the other hand, both methadone and buprenorphine impaired tests of 
tracking and attention and calculation of effect size showed that the effects were 
comparable to BAC of 0.05 % for some of the conditions. 
Large inter-individual variations were observed in pharmacokinetics for both methadone and 
buprenorphine in both blood and oral fluid. Drug concentrations in blood were in general 
very low for buprenorphine as only one third of the results were above the limit of 
qualification. Large ranges of concentrations in blood were observed for both drugs 
especially after the high doses. It was not possible to calculate reliable concentrations in 
blood based on the drug concentrations in oral fluid. 
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14. Implications and future perspectives 
 
Methadone and buprenorphine should be included in future epidemiological studies on risk 
of road traffic crash as well as culpability studies in drivers exposed to these drugs. It would 
also be important to differentiate between OMT use, use in pain treatment and illicit use 
among drivers. 
More studies on patients in OMT are needed, including standardized tests with baseline 
measures, categorization according dose-levels, information on past and present drug use 
and measuring drug concentrations in blood.  
There seems to be sufficient evidence from our clinical study that both drugs have an 
impairing potential relevant to driving performance. The clinical relevance of our findings is, 
however, ambiguous as there were large individual variations. Nonetheless, our findings can 
be used to make recommendations with regards to driving for persons who receive opioids 
short-term, e.g. pain relief after surgical procedures, and for patients when opioid treatment 
is initiated or doses increased. The results should be known by doctors prescribing opioids to 
inform and warn the patients with regards to safe driving or workplace situations. 
Furthermore, knowledge on driving impairment after opioid use can be important for health 
authorities when establishing guidelines for pain treatment and for health requirements for 
driving license.  
Knowledge on reduced alertness, sleepiness and poor balance following opioid intake is 
useful to those performing a CTI or field sobriety test in order to detect impairment 
following opioid intake. 
Future studies where higher doses of these drugs are administered would add valuable 
information, but ethical considerations could prevent approval of such studies.  
Few concentration-effect relationships were found, but the question remains whether there 
are any predisposing factors that could tell us which patients/persons are at particular risk of 
being impaired. Predictive factors to identify persons who are more sensitive to the 
impairing effects of opioids, as well as side effects, will be important not only with regards to 
driving impairment but also to customize drug treatment. Knowledge on receptors and 
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transport across the blood-brain barrier, combined with (pharmaco)genetic analyses, will 
enable adjustment of dosage and choice of drug(s) according to the characteristics of the 
individual patient. 
Finally, our results show that improved methods to analyze low concentrations of 
buprenorphine in blood are required for future studies on low doses of buprenorphine.  
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17. Erratum 
 
− Paper II uses mg ml -1 as unit for blood alcohol concentration, i.e. concentration by 
volume. The correct unit should be concentration by mass in g/kg or ‰. 
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AIMS
The present study assessed the acute effects of methadone and buprenorphine on actual on-road driving performance and
neurocognitive function.
METHODS
Methadone (5 and 10mg per os) and buprenorphine (0.2 and 0.4 mg sublingual) were administered to 22 healthy volunteers in a
five-way, double-blind, randomized, placebo-controlled, double-dummy, cross-over study. Driving performance was assessed
with an on-road driving test. The primary outcome measure was standard deviation of lateral position (SDLP), a measure of road
tracking control. Laboratory tests were used to measure cognitive function (e.g. reaction time and attention) and questionnaires
were used to assess subjective measures of mood and sedation.
RESULTS
There was no significant main effect of treatment on SDLP. Yet, analysis of individual drug-placebo contrast data revealed that
buprenorphine 0.4 mg significantly increased SDLP. Driving impairment was mild and below the impairment threshold of a blood
alcohol concentration of 0.5 mg ml1. Four participants stopped their driving test while under the influence of either opioid due
to sleepiness. Both opioids produced impairments of cognitive task performance and increased sleepiness particularly at the
highest dose.
CONCLUSIONS
Analgesic doses of buprenorphine produced mild impairing effects on driving and related cognitive skills, while methadone
impaired cognitive task performance but not driving performance. Large individual variations were observed for both drugs.
Patients should be informed about the possibility of driving impairment when initiating opioid treatment.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Opioids have been associated with increased crash risk among drivers but it is unknown whether this association
generalizes to all opioids or pertains to specific opioids in particular.
WHAT THIS STUDY ADDS
• An on-road driving test was used to assess the acute effects of analgesic doses of methadone and buprenorphine.
• Buprenorphine 0.4 mg mildly impaired on-road driving.
• Buprenorphine and methadone produced some cognitive and clinical impairments and increased sleepiness, particularly
after the high doses.
Introduction
Opioids are frequently prescribed for the treatment of pain.
The global consumption of opioids was close to 12 billion of
defined daily doses in 2016 [1]. Over the last 20 years, the
global consumption has more than tripled and the share of
synthetic opioids has increased to 39%. In addition,
non-medical use of prescription opioids has been rising
excessively. The large numbers of overprescription, abuse
and overdose death have subsequently generated an opioid
crisis, particularly in North America. In 2016, more than
42 000 persons died in the US as a result of an opioid over-
dose, including prescription opioids [2]. Between January
2016 and September 2017 there were close to 6000 opioid-
related deaths in Canada [3].
Besides the overdoses, mortality among opioid users
has also been associated with accidents related to driving
under the influence. Epidemiological studies have shown
a statistically significant association between opioid use
and road traffic crashes [4]. A European case–control study
that was conducted as part of the research project DRUID
concluded that the average odds ratio of getting seriously
injured or killed in an accident increased by a factor of
2–10 when driving under the influence of medicinal opi-
oids. The latter is comparable to the risk of driving under
the influence of alcohol at blood alcohol concentrations
(BAC) of 0.5–0.8 mg ml1 [5].
Methadone and buprenorphine are opioids widely
used as analgesics and in opioid maintenance treatment. In
blood samples from drivers suspected of drugged driving in
Norway in 2016, methadone was detected in 2% and
buprenorphine in 3% of cases [6]. Approximately 26 000
persons used buprenorphine or methadone on prescription
in Norway in 2016, 18 000 of which used buprenorphine
as an analgesic patch [7]. Opioid prescription in Norway
between 2014–2016 was 12 defined daily doses (DDD) per
1000 inhabitants per day [8].
Methadone is a synthetic, long-acting opioid. Methadone
acts primarily on μ-opioid receptors that are thought to be
particularly important for analgesia, euphoria, respiratory
depression, tolerance and dependence. A regular dose of
methadone in pain treatment is 5–10 mg per os 3–4 times
per day. Buprenorphine is a semi-synthetic partial opioid
agonist/antagonist which binds to δ-receptors, μ-receptors
and κ-receptors in the brain. Buprenorphine has a wide
therapeutic range due to its agonist/antagonist effects, which
limits its depressant effects especially on respiratory and
cardiac functions. A regular dose of buprenorphine in pain
treatment is 0.2–0.4 mg sublingual up to 3–4 times daily.
Although epidemiological studies indicate that opioid
use increases crash risk among drivers, it is less clear
whether driving impairment is caused by each and every
opioid within this group. Traditionally, placebo-
controlled studies have been employed to study differen-
tial effects of opioids on neurocognitive function and
skills related to driving [9]. So far, experimental studies
on the acute effects of methadone and buprenorphine
on driving-related performance in opioid-naïve subjects
have been inconclusive. Few studies on psychomotor
and cognitive performance among healthy volunteers af-
ter administration of a single dose of methadone or
buprenorphine have been performed [10–17]. Only some
of these indicated that methadone 5 mg per os and
buprenorphine 0.3 mg sublingual produced psychomotor
impairment in opioid naïve individuals [13–16]. How-
ever, the clinical relevance of these findings is difficult
to establish as these studies neither included a reference drug
like ethanol, nor included standardized tests to assess impair-
ment [18–20].
Dedicated driving studies to determine and qualify the
clinical relevance of drug effects on driver safety have been
conducted for over 30 years by researchers in the
Netherlands [21]. These studies employed a standardized
on-road driving test that is conducted on a primary high-
way in normal traffic. The primary outcome parameter is
standard deviation of lateral position (SDLP), a measure of
road tracking performance. This measure has been shown
to significantly increase in drivers who are exposed to
acute or repeated doses of sedating drugs [21] and to be
sensitive to BAC as low as 0.35 mg ml1 [22]. Alcohol pro-
duced an exponential rise in SDLP with increasing BACs.
The mean increment in SDLP (i.e. 2.5 cm) that was observed
while driving with a BAC of 0.5 mg ml1 has been
defined as the minimal cut-off value to represent clin-
ical relevance [23]. Recently, the on-road test was used
to compare driving performance of chronic non-cancer
pain patients who received chronic opioid therapy
(e.g. hydromorphone, oxycodone and fentanyl) to that of
matched controls. Driving performance of these patients
did not significantly differ from that of controls indicating
tolerance to certain opioid effects, although large inter-
individual variations were observed [24]. On-road studies
assessing the acute effects of buprenorphine and metha-
done are still lacking.
The aims of this study were to assess and compare the ef-
fects of methadone and buprenorphine on actual driving
and cognitive and psychomotor performance in healthy
volunteers.
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Methods
Subjects
Twenty-two healthy volunteers (11 male, 11 female) aged
23–49 years (mean age 36 years) were included after screen-
ing of 29 volunteers in total. They were recruited via adver-
tisements in local newspapers and poster advertisements in
Maastricht University. None of the volunteers used opioid
analgesics regularly at the time of testing.
Inclusion criteria were: healthy males or females based on
a physical examination, medical history, vital signs, electro-
cardiogram, and the results of blood chemistry and
haematology tests, and urine analysis; age between 23
and 50 years; body mass index (weight/length2) between 19
and 29 kg m2; possession of a valid driving license for
minimum 4 years; driving experience of minimum 5000 km
per year on average; and good sleeper.
Exclusion criteria were: pregnancy or lactation, sleep
disorders; drug or alcohol abuse; use of psychoactive medi-
cation or drug considered to influence the test drugs; exces-
sive alcohol use (>21 units per week); excessive caffeine
use (≥5 cups per day); smoking >6 cigarettes per day;
intake of any opioid within 3 months before the study;
significant disease; and poor metabolism of methadone
due to CYP2B6 polymorphism.
Approval of the study was obtained from the independent
Ethics Committee of Maastricht University and the Academic
Hospital Maastricht in the Netherlands and from the
Regional Committees for Medical and Health Research Ethics
in Norway. This study was conducted according to the code of
ethics on human experimentation established by the
Declaration of Helsinki (1964) and amended in Fortaleza,
Brazil (2013) and in accordance with the Medical Research
Involving Human Subjects Act. Written informed consent
was obtained from all volunteers.
Design and treatments
The study followed a five-way, double-blind, randomized,
placebo-controlled, double-dummy, cross-over design to
compare the acute effects of two single doses of methadone
(5 and 10 mg per os) and buprenorphine (0.2 and 0.4 mg sub-
lingual) with placebo. The minimum washout period be-
tween test days was 10 days.
Similar doses of methadone and buprenorphine have
been administered to opioid naïve users in previous studies
[13–16]. The dose regimen of methadone frequently used
for pain relief is 5–10 mg per os 3–4 times daily.
Buprenorphine is used in pain treatment in doses of
0.2–0.4 mg sublingual up to 3–4 times daily. A single dose of
buprenorphine 0.8 mg sublingual is equivalent to morphine
60 mg per os, while a single dose of methadone 20 mg per
os is equivalent to morphine 60 mg per os [25].
Methadone (methadone capsules and placebo capsules)
and buprenorphine (buprenorphine sublingual tablets and
placebo sublingual tablets) were purchased, blinded and la-
belled by University Pharmacy (Nijmegen, the Netherlands)
and Tiofarma (Oud-Beijerland, the Netherlands), respec-
tively, according to the Good Manufacturing Practice
guidelines.
Procedure
When participants arrived, urine samples were screened for
drugs by using the SureStep™ Drug Screen Cup (Abbott,
Abbott Park, IL, USA); a pregnancy test was performed using
the Alere™ hCG Cassette (Abbott), and breath alcohol was
analysed using Dräger Alcotest 5000 (Drägerwerk AG & Co.,
Lübeck, Germany).
Participants were asked to refrain from consuming caf-
feine (coffee, tea and soft drinks) on test days from awakening
until the end of testing as well as alcohol intake from 24 h
prior to test days. Participants were instructed to have a nor-
mal night of sleep before test days. This was assessed with
the Groningen Subjective Quality of Sleep Questionnaire
[26]. Drug screens assessed for the presence of methamphet-
amine, cocaine, THC, morphine, benzodiazepines and am-
phetamine in urine. On each test day participants received
two capsules containing methadone or placebo and two sub-
lingual tablets containing buprenorphine or placebo, accord-
ing to a double-dummy procedure. Figure 1 provides a
schematic overview of a test day.
Blood was collected using 5-ml Vacutainer® tubes con-
taining sodium fluoride (20 mg) and sodium heparin
(143 IU) (BD Diagnostics, Franklin Lakes, NJ, USA).
Highway driving test
The on-road driving test was performed on a 100 km primary
highway segment in normal traffic [21, 27]. Participants were
instructed to drive with a steady lateral position within the
right traffic lane at a constant speed of 95 km h1 (60 mph).
A licensed driving instructor accompanied the driver. A spe-
cially instrumented vehicle was used to measure standard de-
viation of lateral position (SDLP in cm) or ‘weaving’, the
primary outcome variable [28], see Figure 2. In addition to
SDLP, the standard deviation of speed (SDSP) and mean lat-
eral position (MLP) were measured.
Cognitive and psychomotor tests
The Psychomotor Vigilance Task (PVT) measured sustained
attention by assessing the reaction time in response to a vi-
sual stimulus. The subject had to react to the onset of the
counter as quickly as possible by pressing a response button
[29]. Lapses were defined as a failure to react or any reaction
exceeding 500 msec.
The Critical Tracking Task (CTT) measured the ability to
control an unstable error signal in a first-order compensatory
tracking task [30]. Subjects were instructed to keep an unsta-
ble bar in the middle of a horizontal plane by counteracting
or reversing its movements with the aid of a joystick. The fre-
quency of cursor deviations at which the subject lost control
is the critical frequency.
The Divided Attention Test (DAT) measured the ability to
divide attention between two simultaneously performed
tasks [31]. In the primary task, the subject performed the
same tracking task as described above (CTT), yet at a constant
level of difficulty set at 50% of his or her maximum capacity.
In the secondary task, the subject monitored 24 peripheral
displays in which single digits changed asynchronously at
5 s intervals. Subjects were instructed to remove their foot
from a pedal as rapidly as possible whenever the digit ‘2’
appeared.
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The Useful Field of View Test (UFOV) included three in-
creasingly difficult, visually presented subtests: stimulus
identification, divided attention and selective attention
[32]. The participants had to identify a target presented at a
central fixation point on the screen, and the second and third
subtest included peripheral simultaneous targets as visual
distractors.
The Digit Symbol Substitution Test (DSST) measured ex-
ecutive attention and processing speed [33]. A computerized
version was used [34]. The subject was required to match
digits with a symbol from an encoding list as rapidly as possi-
ble by clicking the corresponding response button.
Postural Balance test (PBT) measured balance using the
AMTI AccuSway System for Balance and Postural Sway
Measurement (Advanced Mechanical Technology, Inc.,
Watertown, MA, USA) force platform [35, 36]. Postural sway
was assessed in two trials (eyes open and eyes closed) by
measuring the length of the path of the centre-of-pressure
(COP), and the area of the 95% confidence ellipse enclosing
the COP (A95).
Vienna Test System – Determination Test (DT/S1) mea-
sured resilience of attention and reaction speed under condi-
tions of sensory stress. The task of the respondent was to
identify various stimuli and to react to them by pressing the
Figure 1
Schematic overview of a test day
Figure 2
Standardized highway driving test. A specially instrumented car was used during the on-road driving test. Participants were instructed to drive
with a steady lateral position between the delineated borders of the right lane with a constant speed of 95 km h1 (60 mph). A licensed driving
instructor was accompanying the participant in the car (upper panels). The standard deviation of lateral position (SDLP in cm) is an index of road
tracking error or ‘weaving’ (lower panel)
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respective corresponding response buttons. This test pre-
sented the stimuli a little faster than would be optimal given
the respondents’ reaction speed, thus resulting in a condition
of sensory stress.
A simplified clinical test of impairment was performed
[37]. The clinical test of impairment, used in Norway by med-
ical doctors working for the police with suspects driving
under the influence of drugs, consists of 25 tests and observa-
tions related to common signs of drug impairment [38]. Five
subtests from the Norwegian clinical test of impairment were
selected: gait-on-line test, turn-on-line test, finger-to-finger
test, finger-to-nose test, and Romberg’s test (standing steady
on one leg for at least 5 s with arms stretched out and eyes
closed) [37]. For each of the five subtests, the performance
was measured and scored as either ‘habitual’, ‘somewhat de-
viant’ or ‘deviant’. An overall impression of the subject,
termed the ‘global impression’, being the sixth subtest, was
graded as either ‘not impaired’, ‘slightly impaired’, ‘moder-
ately impaired’ or ‘obviously impaired’.
Subjective evaluations
Subjective evaluations of mood and apparent sedation were
assessed by using a series of visual analogue scales
(100 mm) [39]. Subjects rated their subjective feelings on
a 16-item mood scale which provided three factor analyti-
cally defined summary scores for ‘alertness’, ‘contented-
ness’ and ‘calmness’.
The Karolinska sleepiness scale is a subjective rating scale
with scores that range from 1, ‘extremely alert,’ to 9, ‘very
sleepy, great effort to keep alert, fighting sleep’ [40]. Reyner
and Horne modified the original scale by adding verbal de-
scriptions to intermediate steps, which do not have any de-
scriptions in the original version [41].
Safety assessment
During test periods, side effects either observed by the inves-
tigator or spontaneously reported by the subject were
recorded.
Pharmacokinetics
Concentrations of methadone and buprenorphine in sam-
ples of whole blood were determined using ultra-high-
performance liquid chromatography–tandem mass spec-
trometry (UHPLC–MS/MS) after 96-well supported liquid
extraction [42], which was slightly modified for the determi-
nation of methadone and buprenorphine by adding relevant
calibration standards. The cut-off concentrations were
0.5 nM for methadone and 0.2 nM for buprenorphine.
Statistics
All measures were analysed using General Linear Model
(GLM) univariate measures. The model included two fixed
factors, i.e. Treatment (5 levels) and Time (2 levels), and a ran-
dom factor for Subjects. Independent of the results of the
main effect of treatment analysis, a drug–placebo contrast as
well as low dose vs. high dose contrast for each opioid was
performed. In addition, a non-inferiority analysis was con-
ducted on SDLP data collected in the highway driving test
to determine clinical relevance of drug-induced changes
relative to placebo. For SDLP, non-inferiority between treat-
ment and placebo was concluded if the upper limit of the
95% CI of the mean difference between drug and placebo
was <2.5 cm. The latter criterion represents a clinically rele-
vant change in SDLP as observed after a BAC of 0.5 mg ml1
[23]. A power analysis showed that in order to detect drug ef-
fects of medium size (f = 0.25) on the within subject variable
(SDLP), a total of 20 participants would be adequate, using a
two-sided t-test with 95% power at a significance level of
5%. All statistical analyses were conducted using SPSS for
Windows (version 25; SPSS Inc., Chicago, IL, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY [43],
and are permanently archived in the Concise Guide to
PHARMACOLOGY 2017/18 [44].
Results
Failure to complete driving test and missing
data
Driving tests had to be terminated prematurely on request of
the participants six times (by four participants). In all cases,
the participants told the driving instructor that they wanted
to terminate the driving session because they felt too sleepy
to continue driving. Driving tests were stopped twice during
methadone 10 mg and buprenorphine 0.4 mg and once fol-
lowing buprenorphine 0.2 and placebo. Two subjects did
not complete all treatment conditions. All data from the on-
road driving test entered the analysis, except one prematurely
terminated ride where driving data was collected for 6 min
only (in the buprenorphine 0.2 mg condition). Extreme out-
liers, defined as deviating more than ±3 SD from the mean
were removed from the respective parameter. In the PBT,
three values were excluded in the eyes open condition, and
five values in the eyes closed condition.
On several test days subjects were not able to complete
neurocognitive tests because of side effects. These data were
registered as missing data and were not included in the anal-
ysis. The number (%) of subjects that were unable to perform
neurocognitive tasks were: PVT n = 3 (14%); CTT n = 5 (23%);
DAT n = 7 (32%); DSST n = 4 (18%); DTS1 n = 7 (32%); UFOV
n = 5 (23%); and PBT n = 10 (45%).
Highway driving test
Table 1 presents a summary of mean (SE) driving and cogni-
tive test performances in all treatment conditions and their
associated GLM statistics.
Analysis of variance showed no significant main effects
of Treatment on SDLP or standard deviation of speed
(SDSP), but a significant effect on mean lateral position
(MLP). Drug–placebo contrasts revealed that buprenorphine
0.4 mg significantly increased SDLP. Non-inferiority was
shown for both methadone conditions as well as the low
dose of buprenorphine. The high dose of buprenorphine
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significantly increased SDLP relative to placebo, but the
95% CI did not include the criterion for clinical relevance
at a BAC of 0.5 mg ml1. Mean changes in SDLP (95% CI)
in all drug conditions are shown in Figure 3.
Cognitive tests
Significant main effects of Treatment and Treatment × Time
were observed in the PVT (reaction time and lapses), the
DAT (control losses, hits and reaction time), Postural balance
(eyes open) and the DSST (correct response). Main effects of
Treatment were found for all tests.
Drug–placebo contrasts revealed that the low dose of
methadone did not affect any of the cognitive parameters, ex-
cept for an increase in postural balance in the eyes closed con-
dition. The high dose of methadone significantly increased
number of lapses (PVT), number of control losses (DAT), reac-
tion time (PVT and DT) and decreased number of hits (DAT),
correct responses (DSST), processing speed (UFOV) and pos-
tural balance. Drug–drug contrast revealed that impairments
observed in reaction time (DT), tracking error (DAT) and cor-
rect responses (DSST) were significantly more pronounced
during the high as compared to the low dose.
The low dose of buprenorphine significantly increased re-
action time (DAT), number of lapses (PVT), number of con-
trol losses (DAT) and postural balance (eyes closed). The
high dose of buprenorphine significantly increased reaction
time (PVT, DAT and DT), number of lapses (PVT), tracking
(CTT), number of control losses (DAT) and decreased number
of hits (DAT), correct responses (DSST), processing speed
(UFOV) and postural balance. Drug–drug contrast revealed
that impairments observed in reaction time (PVT, DAT and
DAT), tracking (CTT), hits (DAT), correct responding (DSST)
and postural balance were significantly more pronounced
during the high as compared to the low dose.
Questionnaires and clinical test of impairment
Table 2 presents mean (SE) scores on questionnaires and the
clinical test of impairment in every treatment condition and
statistics for main effects, drug–placebo and low vs. high dose
contrasts.
Main effects of treatment were observed for all parameters
of the clinical test of impairment except the finger-to-nose
test, the Karolinska sleepiness scale and the factors alertness
and contentedness of the Bond and Lader scale. Main effects
of Treatment × Time were only observed for ratings of sleepi-
ness and alertness.
Drug–placebo contrasts showed that the low dose of
methadone increased sleepiness, clinical impairment rating
(on one parameter) and reduced alertness. The high dose also
increased sleepiness, clinical ratings of impairment (on five
parameters) and alertness. Levels of impairment did not sig-
nificantly differ between both doses on any of these
parameters.
The low dose of buprenorphine increased sleepiness, clin-
ical ratings of impairment (on two parameters) and reduced
alertness and contentedness. The high dose increased sleepi-
ness, clinical ratings of impairment (on four parameters)
and reduced alertness and contentedness. Sleepiness, loss of
alertness and clinical ratings of impairment (on oneT
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parameter) were more pronounced after the high dose as
compared to the low dose.
Side effects
No serious adverse events were observed during the study.
The most frequently reported side effects were nausea,
vomiting, dizziness and tiredness/sleepiness. A summary of
the most frequently reported side effects is given in Table 3.
Pharmacokinetics
Mean (±SD) methadone and buprenorphine blood concen-
trations are presented in Table 4.
Discussion
In the current study the acute effects of methadone (5 mg and
10 mg) and buprenorphine (0.2 mg and 0.4 mg) on on-road
driving, psychomotor and cognitive performance were
assessed. A significant increase in SDLP (i.e. 1.12 cm) during
highway driving was found after 0.4 mg of buprenorphine
as compared to placebo. The low dose of buprenorphine as
well as both doses of methadone did not affect on-road
driving. The influence of both opioids on cognitive task
performance was more prominent. Particularly the high
doses produced performance impairments on several neuro-
cognitive tests. In addition, both drugs increased levels of
sleepiness, reduced alertness and increased ratings of clinical
impairment.
On-road driving data indicated that overall, the influence
of methadone and buprenorphine were mild or even absent.
Non-inferiority was shown for both methadone doses as well
as the low dose of buprenorphine, relative to placebo. The
high dose of buprenorphine significantly increased SDLP rel-
ative to placebo, but the 95% CI did not exceed the BAC
(0.5 mg ml1) criterion for clinical relevance. Mean lateral po-
sition (LP) differed significantly across treatments, mainly be-
cause mean LP was lower after the low dose of
buprenorphine, relative to placebo. During this treatment
condition, subjects chose a lane position that was slightly
left of the lane centre. Mean LP is a control measure to
check if subjects adhered to the instruction of driving in
the centre of the lane. The current data thus indicated that
subjects did not entirely adhere to that instruction during
the lower dose of buprenorphine but instead chose to drive
closer to the midline of the road. One can only speculate
that the choice to drive closer to the middle line reflects
risk-taking behaviour, a strategy for road tracking or other
motivations. Driving impairment was sometimes noticeable
at the individual level across treatment conditions. Four par-
ticipants (18%) decided to prematurely finish their driving
tests while under the influence of buprenorphine (on three
occasions) and methadone (on two occasions) because of
sleepiness while driving. This indicates large inter-
individual variations in driving performance of patients
who receive opioid treatment, some of whom might be im-
paired whilst most are not. Individual differences in impair-
ment levels might be associated to individual differences in
drug concentrations, drug sensitivity and the presence of
side effects that may affect driving.
In contrast to the sparse impairments observed in the
driving tests, all of the cognitive and psychomotor tests
showed dose-related impairment during opioid treatment
conditions as compared to placebo. Seven cognitive tests
were included to measure skills related to driving, such as psy-
chomotor speed (CTT, PVT, DSST, DAT), divided attention
(DAT, UFOV), sustained attention (PVT), reaction speed
(DTS1) and postural balance (PBT). The high doses of
buprenorphine and methadone impaired performance in al-
most every cognitive test. The low doses of buprenorphine
and methadone, on the other hand, only affected some pa-
rameters in the PBT, DAT and PVT and in the PBT, respec-
tively. These findings are in line with previous research
showing that methadone and buprenorphine can impair re-
action time and attention [18]. For several tasks, a significant
Treatment × Time interaction was observed indicating that
opioid effects were more pronounced at 6 h post administra-
tion as compared to 2 h. This suggests that impairments levels
may increase with increasing time on task due to tiredness.
Figure 3
Mean (95% CI) changes in standard deviation of lateral position (SDLP) relative to placebo, in every drug condition
Acute effects of opioids on driving
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Participants indeed felt less alert and more sleepy during the
final part of the test schedule.
Buprenorphine and methadone furthermore increased
sleepiness, ratings of clinical impairment and reduced alert-
ness and contentedness. Well-known side effects of opioid
use such as nausea and vomiting, sleepiness/tiredness and
dizziness were frequently observed, and pronounced in some
subjects. Concentration problems were reported by one sub-
ject only in the high dose buprenorphine condition. Two par-
ticipants reported to experience euphoria, in the methadone
condition. Frequently reported side effects such as sleepiness
and reduced alertness might have contributed significantly to
impairments of driving and neurocognitive function that
were observed after both opioids.
Impairments observed during on-road driving and during
neurocognitive testing in the present study are not necessar-
ily inconsistent. Impairments of neurocognitive test perfor-
mance and on-road driving were most prominent after the
high dose of both opioids and virtually absent for the low
dose. The impaired driving observed after the high dose of
buprenorphine was less than that observed while driving
with a BAC of 0.5 mg ml1. Likewise, when compared to alco-
hol, neurocognitive impairment observed in the DSST and
DAT (i.e. reaction time) in the present study were equivalent
to impairments previously observed at BACs between 0.2 and
0.8 mg ml1 [45]. It has been demonstrated that the presence
or absence of impairments in neurocognitive tests are rela-
tively poor predictors of drug effects in the on-road test [46,
47]. In part, the lack of correlation between drug-induced im-
pairment during on-road and neurocognitive performance
might be explained by a lack of overlap in their underlying
cognitive domains [20]. The SDLP of the on-road driving test
primarily measures sustained attention and road tracking per-
formance. As such, it measures operational performance that
is highly overlearned and automated and which does not re-
quire higher order cognitive control that one typically ob-
serves during complex task performance as assessed with
neurocognitive tasks of executive function [20, 48]. Alterna-
tively, participants in the present study may have been able
to compensate for their level of drowsiness to some degree
Table 3
Side effects occurring in >2 subjects
Side effects
Placebo
(n = 22) n (%)
Buprenorphine 0.2 mg
(n = 22) n (%)
Buprenorphine 0.4 mg
(n = 21) n (%)
Methadone 5 mg
(n = 20) n (%)
Methadone 10 mg
(n = 22) n (%)
Nausea 1 (5) 5 (23) 15 (71) 4 (20) 11 (50)
Vomiting – – 9 (43) 1 (5) 4 (18)
Tiredness 7 (32) 9 (41) 8 (38) 11 (55) 11 (50)
Sleepiness 6 (27) 10 (45) 6 (29) 7 (35) 7 (32)
Headache 2 (9) 2 (9) 2 (10) 4 (20) 1 (5)
Warm/sweaty – 1 (5) 5 (24) 1 (5) 4 (18)
Clammy – – 3 (14) 1 (5) –
Paleness – – 3 (14) – 4 (18)
Dizziness – 7 (32) 11 (52) 7 (35) 14 (64)
Itching – – – 1 (5) 3 (14)
Concentration
problems
2 (9) 2 (9) 1 (5) – –
Euphoria – – – 1 (5) 2 (9)
Drowsiness – 1 (5) 2 (10) – 1 (5)
Dry mouth 2 (9) 2 (9) 1 (5) – 3 (14)
Table 4
Drug concentrations in whole blood in all opioid condition as a function of the time after administration (mean ± SD) (nM)
Time post drug (h) Buprenorphine 0.2 mg n Buprenorphine 0.4 mg n Methadone 5 mg n Methadone 10 mg n
1 0.16 (0.08) 20 0.30 (0.13) 21 14.44 (11.82) 19 19.18 (16.33) 20
2 0.21 (0.10) 21 0.38 (0.18) 21 30.10 (10.33) 20 53.73 (21.06) 20
3.5 0.15 (0.09) 22 0.28 (0.12) 21 36.28 (9.35) 20 65.13 (15.30) 20
6.5 0.05 (0.04) 21 0.09 (0.05) 20 25.83 (6.28) 19 51.78 (8.33) 20
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when confronted with real-life risk situations such as driving
in traffic. The need to compensate is less urgent when
performing neurocognitive tests in a laboratory setting.
A number of limitations of the current study should be
considered. The driving tests were performed at the time at
which the maximum concentration of drug in blood (Tmax)
is observed during the methadone conditions but slightly af-
ter the expected Tmax during buprenorphine. This could im-
ply that driving impairment observed after buprenorphine
might have been more pronounced when measured at Tmax.
However, buprenorphine concentrations assessed prior to
driving were very much in the range of the expected maxi-
mum concentration in blood (Cmax), which indicates that
the present buprenorphine data do represent impairment
levels at maximal buprenorphine concentrations. In addi-
tion, many subjects suffered from adverse events that some-
times prevented data from being collected. Driving
impairment in tests that were stopped prematurely might
have progressively increased if the test had continued. Like-
wise, a number of cognitive tasks were never conducted
because subjects were unable to perform the task. None of
these ‘missing’ data contributed to performance measures
that were established in this study. This could mean that the
impairment levels observed in the present study might be
an underestimation of impairment levels that can be
expected in real life.
We conclude that overall, the influence of single analgesic
doses of buprenorphine and methadone on actual driving
performance were mild. Cognitive functions were somewhat
more affected. At the group level, impairment was most evi-
dent following the high dose of buprenorphine but its magni-
tude was below the BAC (0.5 mg ml1) criterion threshold of
clinical relevance. For both drugs, more pronounced effects
were found after the higher dose. At the individual level,
however, four participants felt unsafe and discontinued their
driving test while under the influence of buprenorphine or
methadone. Based on these findings it is therefore impossible
to state that use of buprenorphine and methadone will not
impair driving in any patient. Consequently, patients should
always be informed about the potential driving impairment
that might be caused by buprenorphine and methadone.
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ABSTRACT 
Background  
Few studies have investigated neurocognitive effects of methadone and buprenorphine while 
measuring drug concentrations in blood. We studied the pharmacokinetics of methadone and 
buprenorphine in blood and oral fluid after single dose administration as well as the 
correlation between effects on neurocognitive functions in relation to concentrations in blood. 
Methods 
A five-way, double-blind, randomized, placebo-controlled, double-dummy, cross-over study 
was performed to study the pharmacokinetics and neurocognitive effects of methadone (5 and 
10 mg per oral) and buprenorphine (0.2 and 0.4 mg sublingual) in 22 healthy volunteers.  
Blood and oral fluid were collected throughout the test days and drug concentrations in both 
matrixes were analysed using UHPLC-MS/MS. On-road driving testing, neurocognitive 
computerized tests and subjective questionnaires were performed.  
Results 
Large individual variations in concentrations of methadone and buprenorphine in blood and 
oral fluid, and accordingly oral fluid/blood drug concentration ratios, were observed. E.g. the 
mean ratio 6.5 hours after drug administration was 2.0 (range 0.49 – 7.39) for methadone after 
both doses. Buprenorphine was not detected above the limit of quantification in blood after 
6.5 hours. Correlations between buprenorphine concentrations in blood were found for 
standard deviation of lateral position (SDLP) of the driving test (r=.477, p=0.002), and 
measures of reaction time, divided attention and balance test, as well as alertness, 
contentedness and sleepiness. No significant correlations were found for methadone. 
Conclusions 
Concentrations of methadone and buprenorphine in blood and oral fluid showed large inter-
individual variations. Concentration-effect correlations were found for some tests after 
administration of buprenorphine, but not for methadone. 
 
Key words: Oral fluid, blood, methadone, buprenorphine, neurocognitive 
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INTRODUCTION 
Opioids, like methadone and buprenorphine, are widely used as analgesics, mainly to relieve 
moderate to severe pain for short time periods, but also for long-term treatment of patients 
with chronic pain and cancer and for maintenance treatment of patients with opioid use 
disorder.  
Previous studies on the acute effects of a single dose of methadone on psychomotor or 
cognitive functions in healthy volunteers did not measure drug concentrations in blood (1-3). 
Only one study measured buprenorphine concentrations in plasma while testing psychomotor 
and cognitive effects (4) whereas other studies on performance did not include 
pharmacokinetic measurements of buprenorphine (5-8). Drug measurements in blood are 
essential when establishing concentration-effect relationships. 
The use of oral fluid for detection and quantification of drugs of abuse has increased during 
the last decade. The relationship between drug concentrations in blood and oral fluid has been 
studied for several opioids and low correlations between oral fluid and blood concentrations 
were observed and their ratios varied widely (9-11). The latter indicates that opioid 
concentrations in oral fluid cannot be used to reliably estimate opioid concentrations in blood. 
Few studies have measured buprenorphine in oral fluid (12), while previous studies of 
methadone have indicated oral fluid/blood concentration ratios and oral fluid/plasma ratios 
ranging from 0.5 to 7.2 (10, 11). No studies have measured concentrations of buprenorphine 
in oral fluid after single dose administration. 
Both methadone and buprenorphine can impair cognitive function and may affect a patient’s 
ability to drive safely (13, 14).With regards to opioids and traffic safety in general, most 
epidemiological studies have found significant associations between opioid use and road 
traffic crashes (15) while experimental studies have found that opioids can have some 
moderate effects on neurocognitive performance without a clear dose relationship (16).  
A recent study on the effects of analgesic doses of methadone (5 and 10 mg) and 
buprenorphine (0.2 and 0.4 mg) on driving and related skills showed that both drugs caused 
impairment in opioid-naïve subjects (17). Buprenorphine produced mild impairment of 
driving, while more pronounced and dose dependent impairment of cognitive skills related to 
driving were found for both opioids, in line with previous studies (2, 8).   
 Strand 2019. Pharmacokinetics of methadone and buprenorphine, p. 4  
Positive correlations between drug concentrations in blood and impairment of neurocognitive 
function have previously been reported for some drugs, although less clear for opioids than 
for other drug classes; for references see (18). This indicates some uncertainty for methadone 
and buprenorphine with respect to the association between blood drug concentrations and 
their impairing effects. Establishment of concentration-effect relations for both drugs are of 
relevance for assigning per se limits for driving under the influence of these compounds. For 
example, Norway implemented legal limits for methadone and buprenorphine in 2012 in the 
Road Traffic Act. The law was updated in 2016. Eventually, three levels of limits were 
established, comparable to traffic relevant impairment seen at blood alcohol concentrations 
(BAC) of 0.02, 0.05 and 0.12 % (18). The thresholds for methadone and buprenorphine 
corresponding to 0.02 % BAC limits were set at 80 nM and 0.8 nM, respectively. 
The current paper is a follow-up publication of our previous study (17), which suggested a 
relation between drug dose and neurocognitive impairment, which has, to our knowledge, not 
been studied previously (19). In the present study we investigated the association between 
methadone and buprenorphine concentrations in blood and psychomotor and cognitive 
performance.  
This study aimed to answer whether drug concentrations in oral fluid, would reflect drug 
concentrations in blood. Furthermore, we wanted to study whether concentrations of 
methadone and buprenorphine in blood are correlated to the level of impairment that these 
compounds produce on actual driving and neurocognitive function. 
 
MATERIALS AND METHODS 
The methods used have been described in detail by Strand et al. (17). 
Subjects 
Twenty-two healthy volunteers (11 males, 11 females) aged 23-49 years (mean age 36 years) 
with a mean body mass index (weight/lenght
2
) of 24.2 kg/m
2
 (range 19.6-29.1) were included. 
They were recruited via advertisements in local newspapers and poster advertisements at 
Maastricht University.  
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Inclusion criteria were: males or females with good health based on a physical examination 
and the results of blood chemistry and haematology tests; age between 23 and 50 years; body 
mass index  between 19 and 29 kg/m
2
; and experienced drivers. 
Exclusion criteria were: pregnancy or lactation, sleep disorders; drug or alcohol abuse; use of 
psychoactive medication; excessive alcohol and/or caffeine use; smoking >6 cigarettes per 
day; intake of any opioid within 3 months before the study; and significant disease. 
Ethical approval for the study was obtained from the independent Ethics Committee of 
Maastricht University and the Academic Hospital Maastricht in The Netherlands and from the 
Regional Committees for Medical and Health Research Ethics in Norway. This study was 
conducted according to the code of ethics on human experimentation established by the 
declaration of Helsinki (1964) and amended in Fortaleza, Brazil (2013) and in accordance 
with the Medical Research Involving Human Subjects Act. Written informed consent was 
obtained from all volunteers.  
Design and treatments 
The acute effects of two single doses of buprenorphine (0.2 and 0.4 mg sublingual) and 
methadone (5 and 10 mg per oral) were studied in a five-way, double-blind, randomized, 
placebo-controlled, double-dummy, cross-over study. The minimum wash-out period between 
the test days was 10 days. Similar doses of methadone and buprenorphine have been 
administered to opioid naïve volunteers in previous studies (1-3, 7). 
Methadone (methadone capsules and placebo capsules) and buprenorphine (buprenorphine 
sublingual tablets and placebo sublingual tablets) were purchased, blinded and labelled by 
Tiofarma (Oud-Beijerland, the Netherlands) and the University Pharmacy of Nijmegen (the 
Netherlands), respectively, according to the Good Manufacturing Practice guidelines.   
Procedure 
On the test days, urine samples were screened for drugs by using the SureStep™ Drug Screen 
Cup (Abbott, Abbott Park, IL, USA); a pregnancy test was performed using the Alere™ hCG 
Cassette (Abbott), and breath alcohol was analysed using Dräger Alcotest 5000 (Drägerwerk 
AG & Co., Lübeck, Germany). Blood samples were collected 1, 2, 3.5 and 6.5 hours after 
drug administration, while the highway driving test was performed after 4 hours and the 
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neurocognitive tests and subjective evaluations after 2 and 6 hours (morning and afternoon 
condition).  
Pharmacokinetic assessments and drug analysis 
The analytical results in blood and oral fluid samples for two subjects were excluded from the 
data analysis due to incorrect labelling of the samples.  
Blood was collected using 5 ml Vacutainer® tubes containing Sodium Fluoride (20 mg) and 
Sodium Heparin (143 IU) (BD Diagnostics, Franklin Lakes, NJ, USA). Drug concentrations 
in whole blood samples were determined using UHPLC-MS/MS (20);  the method was 
slightly modified for the determination of methadone and buprenorphine by adding relevant 
calibration standards. The limits of quantification (LOQ) in blood were 0.5 nM for methadone 
and 0.2 nM for buprenorphine, while the limits of detection (LOD) were 0.15 nM for 
methadone and 0.02 nM for buprenorphine. 
Oral fluid was collected using Quantisal™ Oral Fluid Collection Device (Abbot, Lake Bluff, 
IL, USA). Concentrations of methadone and buprenorphine in oral fluid were determined 
using ultra-high performance liquid chromatography - tandem mass spectrometry (UHPLC-
MS/MS) after 96-well supported liquid extraction (21). The LOQ in oral fluid was 1 nM for 
both methadone and buprenorphine, while the LOD was 0.15 nM for both drugs. The oral 
fluid samples were diluted with 3 ml preservative buffer that was present in the Quantisal 
device. Therefore, the samples were weighed to determine the amount of oral fluid collected 
in order to calculate concentrations in neat oral fluid, which were calculated by multiplying 
the concentration of drug in oral fluid by with the oral fluid weight (in g) + 3 g, and divide 
this by the oral fluid weight.  
All data was included in the calculation of median values for blood and oral fluid 
concentrations shown in Figure 1. An outlier was defined as any value exceeding the third 
quartile plus the interquartile range × 1.5 or being less than the first quartile minus the 
interquartile range × 1.5. 
Highway driving test 
The on-road driving test was performed on a 100 km primary highway segment in normal 
traffic with duration of approximately one hour (22, 23). Participants were instructed to drive 
with a steady lateral position within the right traffic lane at a constant speed of 95 km/h (60 
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mph) and a specially instrumented vehicle was used to measure standard deviation of lateral 
position (SDLP) in centimetres, also named “weaving” (24). 
Cognitive and psychomotor tests  
A detailed description of the tests used are given in Strand et al. (17). The Psychomotor 
Vigilance Task (PVT) measured sustained attention by assessing the reaction time in response 
to a visual stimulus (25). The Critical Tracking Task (CTT) measured the ability to control an 
unstable error signal in a compensatory tracking task (26). The Divided Attention Test (DAT) 
measured the ability to divide attention between two simultaneously performed tasks (27). 
The Useful Field of View Test (UFOV) measured stimulus identification, divided attention, 
and selective attention (28). The Digit Symbol Substitution Test (DSST) measured executive 
attention and processing speed (29). Postural Balance test (PBT) measured balance in two 
trials (eyes open and eyes closed) (30, 31). The Determination Test (DT/S1) of the Vienna 
Test System measured resilience of attention and reaction speed under conditions of sensory 
stress (32).  
A clinical test of impairment was performed 2 hours after drug administration, consisting of 
the following subtests: gait-on-line, turn-on-line, finger-to-finger, finger-to-nose, and 
Romberg’s test (standing steady on one leg for at least 5 seconds with arms stretched out and 
eyes closed) (33). An overall impression of the subject, termed the “global impression”, being 
the “sixth subtest”, was graded as either “not impaired”, “slightly impaired”, “moderately 
impaired” or “obviously impaired”. 
Subjective evaluations 
Subjective evaluations of mood and apparent sedation were assessed by using a series of 
visual analogue scales (100 mm) (Bond and Lader) (34). Subjects rated their subjective 
feelings and summary scores were found for “alertness”, ”contentedness”, and “calmness”. 
The Karolinska sleepiness scale, modified by Reyner and Horne, has scores that range from 1 
(“extremely alert,”) to 9 (“very sleepy, great effort to keep alert, fighting sleep”) (35, 36). 
Statistics 
Bivariate correlations were used to evaluate associations between opioid concentrations in 
blood and opioid induced changes in driving and neurocognitive performance (concentration 
in blood x test). The concentrations measured  3.5 hours after administration were used to 
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calculate correlation with the driving test, while the concentrations measured after 2  and 6.5 
hours were used to calculate correlation with the neurocognitive tests and subjective 
evaluations performed in the morning and afternoon, respectively. Correlations were 
calculated for the morning and afternoon separately due to the risk of acute tolerance to the 
drug effects. To calculate drug induced change, performance scores during placebo were 
subtracted from performance scores during treatment with methadone and buprenorphine. The 
statistical analyses were conducted using SPSS® Statistics version 25 (IBM Corporation, 
Armonk, NY, USA).  
 
RESULTS 
Pharmacokinetics 
Blood 
Mean concentrations of methadone and buprenorphine in whole blood are shown in Figure 1.  
After administration of methadone, concentrations were above the LOQ of 0.5 nM in all 
samples, except from one subject, who did not have methadone concentrations above the 
LOD 1 hour after both doses. The high dose of methadone caused mean concentrations that 
were almost twice as high as concentrations seen after the low dose, see Figure 1. Maximum 
concentrations were observed 3.5 hours after drug administration for both doses. 
For buprenorphine, only 36% of the blood samples had concentrations above the LOQ of 0.2 
nM. Only one subject had a concentration of buprenorphine in blood above the LOQ 6.5 
hours after administration of 0.4 mg buprenorphine. Nine subjects did not have concentrations 
of buprenorphine in blood above the LOQ at any sampling time after administration of the 
low dose. After the high dose all subjects had buprenorphine concentrations in blood above 
the LOQ in two or more samples. In general, the high dose (0.4 mg) caused mean 
concentrations approximately twice as high as those after the lower dose at all time points of 
blood sampling, see Figure 1. Estimated concentrations below the LOQ, and above the LOD, 
are included in Figure 1. The mean maximum concentration (Cmax) was observed 2 hours after 
drug administration for both the low and the high dose.  
Oral fluid 
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Mean concentrations of methadone and buprenorphine in neat oral fluid are shown in Figure 
1. The curve profiles for drug concentration versus time were completely different for oral 
fluid as compared to blood for both drugs.  
Methadone was detected in low concentrations in oral fluid in four subjects up to 16 days 
after intake of the drug, as measured in oral fluid samples on later test days when methadone 
was not administered. The concentrations ranged from 0.1 to 0.28 nM. This occurred after 
intake of both 5 and 10 mg of methadone, and all subjects were female.  
Buprenorphine was only detected in oral fluid from collected on the day of drug 
administration. The mean buprenorphine concentrations in oral fluid decreased to a very low 
level after 6.5 hours, see Figure 1. 
Concentration ratios in oral fluid/blood  
A box-plot of all oral fluid/blood concentration ratios at the different times of sampling is 
shown in Figure 2. Only concentrations exceeding the LOQ were used to calculate oral 
fluid/blood ratios. There was a substantial difference between methadone and buprenorphine 
ratios.  
Highway driving test 
The results of the correlation analysis between opioid concentrations in blood and changes in 
driving performance are shown in Table 1. 
There was a significant correlation between the concentrations of buprenorphine in blood and 
changes in SDLP (r=.477, p=0.002) and MLP (r=.323, p=0.039). For methadone, no 
significant correlation between concentrations and driving performance was observed. Scatter 
plots of change in SDLP as a function of opioid concentrations in blood are shown in Figure 
3.  
 Cognitive and psychomotor tests 
The results of the correlation analyses between opioid concentrations in blood and changes in 
neurocognitive functions in the morning are shown in Table 1. 
There was a significant correlation between concentrations of buprenorphine in blood and the 
following measures in the morning: PVT reaction time (r=.369, p=0.016), PVT lapses 
(r=.327, p=0.035), DAT reaction time (r=.335, p=0.032), DSST (r=-.342, p=0.027), PBT eyes 
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open (r=.428, p=0.005) and PBT eyes closed (r=.383, p=0.013). During the afternoon a 
significant correlation was found for buprenorphine in DAT hits (r=-.335, p=0.040). 
Methadone concentration significantly correlated with change in DSST (r=-.371, p=0.022) in 
the afternoon.    
Subjective evaluations and clinical test of impairment 
Significant correlations between concentrations of buprenorphine in blood and measured 
alertness (r=.573, p=0.000), contentedness (r=.417, p=0.006) and sleepiness (r=.408, p=0.007) 
were found in the morning. In the afternoon, changes in alertness (r=.358, p=0.022) were 
significantly correlated to buprenorphine concentrations in blood.   
 
DISCUSSION 
Our study found large individual variations in blood and oral fluid concentrations for both 
drugs. Mean concentrations of methadone in blood were lower than previously reported 
concentrations after similar doses in healthy volunteers (37). Concentrations of methadone in 
plasma showed large individual differences after intake of methadone 20 mg per oral in opiate 
dependent subjects during detoxification, ranging from concentrations similar to those found 
in our study, up to 200 nM (38). Previous studies where buprenorphine has been administered 
to healthy volunteers have in most cases given higher doses than those in the current study, 
i.e. doses of 4 and 8 mg sublingual (39-41). If using their data to estimate the expected drug 
concentrations in blood after administration of 0.2 and 0.4 mg doses, the extrapolated 
concentrations of buprenorphine would be higher than those found in our study. This could 
indicate some type of saturation pharmacokinetics for buprenorphine when higher doses are 
administered. 
Cmax of methadone in blood was measured 3.5 hours after administration, which is within the 
range previously established as time to maximum concentration after oral intake. 
Buprenorphine was administered sublingual, which is likely the reason for the rapid 
absorption observed as compared to methadone with a Cmax of buprenorphine after two hours 
(42). 
Our findings indicate that the doses given caused detectable concentrations of buprenorphine 
in oral fluid up to approximately 6.5 hours after administration. A previous study reported that 
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after acute sublingual administration of buprenorphine saliva and plasma levels were 
substantially elevated during the first twelve hours (12). The oral fluid/blood ratios for 
buprenorphine were more than 1,000 times higher than those of methadone. This is most 
likely due to presence of residual buprenorphine in the oral cavity after sublingual 
administration. This also caused the oral fluid/blood concentration ratios for buprenorphine to 
be extremely large during the first hours. Buprenorphine concentrations in blood were below 
the LOQ after 6.5 hours, at a time where one could expect a steady state between blood and 
oral fluid, thus a reliable oral fluid/blood concentration could not be calculated at equilibrium.  
The curve for methadone in oral fluid shows a “dip” at +3.5 hours after drug administration. It 
might be due to the intake of lunch, even though not all participants had lunch due to side 
effects like nausea. This effect has previously also been described after intake of zopiclone 
(43), and it has been suggested that the intake of a meal will increase saliva secretion and 
thereby dilute the oral fluid sample. This effect was however not observed for buprenorphine. 
Significant correlations were found for buprenorphine concentrations in blood and its effect 
on driving (SDLP) and neurocognitive performance. No correlation was found between 
methadone concentrations in blood and performance, except for the DSST.   
Most of the significant correlations were found for buprenorphine in the morning. This 
coincides with the time of maximum concentration of buprenorphine in blood. In a previous 
study, Zacny et al. (8) found a dose dependant reduction in DSST performance, as did we 
(17). In the present study we observed a blood buprenorphine concentration relationship to the 
outcome of the DSST. However, the tests that showed dose-dependent effects were not 
always coinciding with those where a concentration-dependent effect was found, even though 
the higher doses of methadone and buprenorphine caused higher mean concentrations in 
blood as compared to the lower doses. Dose-dependent effects were found only in about half 
of the tests showing correlation with the drug concentrations. E.g. in the morning condition 
concentration-correlations were found for the SDLP, MLP, PVT, DAT, DSST and PBT (eyes 
open and closed), while dose-effect was seen for the DAT, DSST, DT/S1 and PBT (eyes 
open), after buprenorphine administration (17). The main explanation for this discrepancy 
between dose-effects and drug concentration-effects is probably that the degree of impairment 
also depends on factors other than drug concentrations in blood, i.e. drug transport across the 
blood-brain barrier (44, 45) and the activation of opioid-receptors (46). Future studies are 
required to add knowledge to this subject. 
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Significant correlations were found between buprenorphine concentrations in blood and 
alertness and contentedness in the morning condition, as well as alertness in the afternoon 
condition, indicating that subjects felt less alert and less content depending on the 
buprenorphine concentration in blood. Furthermore, a significant correlation was found for 
KSS in the morning condition, showing that the volunteers felt more sleepy a few hours after 
buprenorphine administration depending on the blood buprenorphine concentration. 
No correlation was found between methadone concentrations in blood and neurocognitive 
performance. Methadone is a full agonist, whereas buprenorphine is a partial agonist, to the 
opioid receptors. For this reason, one would expect to see more effects after methadone 
administration as compared to buprenorphine than what we observed in our study. However, 
both the doses administered and the concentration levels measured in blood were relatively 
low. It is possible that the drug concentrations in blood were too low to detect concentration-
effect correlations at a larger scale. A previous review on the effects of morphine on 
neurocognitive performance in healthy volunteers showed that there was a concentration-
effect relationship (47) and concentration-related effects on cognition and motor control have 
been reported after morphine administration (48). Single doses of buprenorphine 0.8 mg 
sublingual and methadone 20 mg per oral are considered equianalgesic to a single dose of 
morphine 60 mg per oral (49). Our findings show, however, that 0.4 mg of buprenorphine 
produced more significant effects on driving and neurocognitive tests than 10 mg of 
methadone. As buprenorphine 0.4 mg did not seem to be equipotent to methadone 10 mg with 
respect to those effects, this might be the reason for the lack of concentration-effect 
relationship for methadone.   
In 2012/2016, Norway implemented legislative limits for non-alcohol drugs in the Road 
Traffic Act, aiming to have a more similar handling of cases of driving under the influence of 
alcohol and psychoactive drugs. In our study, only four subjects had a maximum 
concentration of methadone in blood higher than the legislative limit of 80 nM (comparable to 
a BAC of 0.02 %) implemented in the Norwegian Road Traffic Act. None of the measured 
concentrations of buprenorphine in blood in our study exceeded the Norwegian legislative 
limit of 0.8 nM for buprenorphine. From the on-road driving test we found that only the high 
dose of buprenorphine caused significant impairment as compared to placebo (17). The mean 
concentration of buprenorphine in blood at the time of the driving test was 0.28 nM (range 
0.08-0.48). It seems that the legislative limit for buprenorphine at 0.8 nM is rather liberal and 
could be adjusted downwards. None of the doses of methadone caused a significant change in 
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driving performance compared to placebo, this in accordance with the mean concentrations 
observed in blood that were below the legislative limit comparable to a BAC of 0.02 %.  
Furthermore, these findings could indicate that low concentrations of opioids in blood might 
not be the best indicator to determine whether a patient can drive safely. An individual 
evaluation of the degree of impairment and fitness to drive is probably a more reliable tool for 
assessing possible driving impairment among patients in opioid treatment. 
The large inter-individual variations in blood and oral fluid concentrations for also caused 
wide ranges of the oral fluid/blood concentration ratios. A mean oral fluid/blood 
concentration ratio for methadone of 0.7 has previously been reported (10) and oral 
fluid/plasma concentration ratios between 0.5 and 7.2 (11). The ratios for methadone 6.5 
hours after drug administration, at a point where steady state between oral fluid and blood was 
probably achieved, were similar to these ratios.  
We conclude that large inter-individual variations were observed in both blood and oral fluid 
concentrations after single dose administration of methadone and buprenorphine. 
Furthermore, correlations were found between buprenorphine concentrations in blood and 
effects on driving performance, subjective ratings and neurocognitive function, but no such 
correlations were found after methadone administration.  
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 Figure 1 Mean (SD) concentrations of methadone and buprenorphine in oral fluid and whole 
blood (nM) after administration of 5 and 10 mg methadone per oral (po) and 0.2 and 0.4 mg 
buprenorphine sublingual (sl). 
______  Oral fluid 
- - - - - -  Blood
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Figure 2 Boxplots showing rations between concentrations of methadone in oral fluid 
compared to whole blood. 
× = maximum outliers 
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Table 1 Correlation between concentrations of buprenorphine and methadone in blood and 
significant effects on highway driving test, cognitive and psychomotor tests and subjective 
evaluations. All correlations given in the table are from data collected in the morning 
condition (2 hours after drug administration for the neurocognitive tests and 3.5 hours for the 
driving test). 
ns = not significant 
 
Performance parameters Correlation blood concentration x Performance 
 
 
Buprenorphine Methadone 
Highway driving test 
Standard deviation of lateral position (cm) 
 
r=.477 (p=0.002) 
 
ns 
Standard deviation of speed (km/h) ns ns 
Mean lateral position (cm) r=.323 (p=0.039) ns 
Psychomotor Vigilance Test  
Mean reaction time (ms) 
 
r=.369 (p=0.016) 
ns 
Lapses (#) r=.327 (p=0.035) ns 
Critical Tracking Test 
Critical lambda (rad s-1) 
 
ns 
ns 
Divided Attention Test 
Tracking errors (mm) 
 
ns 
ns 
Control losses (#) ns ns 
Hits (#) ns ns 
False alarms (#) ns ns 
Reaction time (ms) r=.335 (p=0.032) ns 
Digit Symbol Substitution Test 
Correct responses (#) 
 
r=-.342 (p=0.027) 
ns 
Determination Test version S1 
Median reaction time (ms) 
 
ns 
ns 
Correct responses (#) ns ns 
Useful Field of View  
Processing speed 
 
ns 
ns 
Postural Balance test 
Eyes open – ln area 95 (cm2)  
 
r=.428 (p=0.005) 
ns 
Eyes closed – ln area 95 (cm2)  r=.383 (p=0.013) ns 
Karolinska sleepiness scale r=.408 (p=0.007) ns 
Simplified clinical test of impairment 
Walk-on-line 
 
ns 
ns 
Gait-on-line ns ns 
Finger-finger-test ns ns 
Finger-nose-test ns ns 
Romberg’s test ns ns 
Overall impression ns ns 
Bond&Lader 
Alertness 
 
r=.573 (p=0.000) 
ns 
Contentedness r=.417 (p=0.006) ns 
Calmness ns  ns  
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Figure 3 Scatter plot showing the relationship between differences in standard deviation of 
lateral position (SDLP) from placebo and concentrations of buprenorphine and methadone in 
whole blood. A significant correlation was found between concentration of buprenorphine in 
blood and change in SDLP as compared to the placebo condition. 
 
 
 
